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Methyl sulfonamide substituents improve the
pharmacokinetic properties of bicyclic 2-pyridone
based Chlamydia trachomatis inhibitors
Martina Kulén,†ab Carlos Núñez-Otero, †bde Andrew G. Cairns,ab Jim Silver,bcd
Anders E. G. Lindgren,ab Emma Wede,bcd Pardeep Singh,ab Katarina Vielfort,bcd
Wael Bahnan,‡bcd James A. D. Good,§ab Richard Svensson,fg Sven Bergström,*bcd
Åsa Gylfe*bde and Fredrik Almqvist*ab
Chlamydia trachomatis infections are a global health problem and new approaches to treat C. trachomatis
with drugs of high specificity would be valuable. A library of substituted ring fused 2-pyridones has been
synthesized and evaluated for their ability to attenuate C. trachomatis infectivity. In vivo pharmacokinetic
studies were performed, with the best candidates demonstrating that a C8-methylsulfonamide substituent
improved pharmacokinetic properties important for oral administration. C8-Methyl sulfonamide analogue
30 inhibited C. trachomatis infectivity in low micromolar concentrations. Further pharmacokinetic
evaluation at an oral dose of 10 mg kg−1 showed an apparent bioavailability of 41%, compared to C8-
cyclopropyl and -methoxy analogues which had negligible oral uptake. In vitro ADME (absorption,
distribution, metabolism and excretion) testing of solubility and Caco-2 cell permeability revealed that both
solubility and permeability is greatly improved with the C8-methyl sulfonamide 30, effectively moving it
from BCS (Biopharmaceutical Classification System) class IV to II.
Introduction
Chlamydia trachomatis is the most common cause of sexually
transmitted disease and infectious blinding, infecting over
one hundred million individuals globally every year.1 Chronic
genital infections can cause infertility in women and
inflammatory arthritis in both genders.2 Chlamydia is a Gram
negative obligate intracellular bacterium with a unique
developmental cycle. The extracellular form, elementary body
(EB), attaches and enters the host cell.3 Once intracellular,
Chlamydia differentiates to the non-infectious replicative
intracellular form, reticulate body (RB).4 RBs replicate within
a vacuole-like structure termed inclusion for 36 to 72 hours.
After replication, RBs differentiate back to EBs, which
abandon the host cell by lysis or extrusion.5
Infections with C. trachomatis are routinely treated with
doxycycline or azithromycin, with high efficacy.6 However,
the treatment of uncomplicated infections with broad-
spectrum antibiotics disturbs the commensal flora in both
the short and long term.7 Moreover, exposure to antibiotics
contributes to the overall selective pressure on bacterial
resistance.8 Anti-virulence compounds with selective effect on
Chlamydia would not only reduce the use of important broad-
spectrum antibiotics but also reduce side effects on the
normal flora and the resulting selection for antibiotic
resistant strains.
In search for potent anti-virulence compounds targeting
C. trachomatis we previously identified compound 1 (Fig. 1)
as a possible candidate.9 When C. trachomatis was treated
with this compound at 2.5 μM in vitro, progeny was produced
but their ability to infect new cells was attenuated. It was
observed that inhibition of the pathogenic ability of C.
trachomatis was partly due to an effect on glucose uptake.9
Introduction of an amine substituent in the C6-position and
saturation of the C2–C3 double bond resulted in compound
2, with higher activity and better physiochemical properties
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than its precursor.10 Further development by exchanging the
hydrolysable C3-phenyl amide to non-hydrolysable amide
isosteres resulted in the potent 1,2,3-triazole analogue 3
(Fig. 1).11 The ring-fused 2-pyridone analogues 2 and 3
inhibit Chlamydial infectivity (EC50 < 60 nM) in a cell based
assay without effecting host microbiota and showed no
mutagenic potential when assessed with the Ames test.11,12
Ideally a drug for the genital C. trachomatis infection would
be administered orally. In vitro ADME (absorption,
distribution, metabolism, excretion) testing regarding
solubility and permeability was performed on 2 (not shown),
yielding poor solubility and moderate permeability. Both
compounds were also tested in vivo, via intravenous (IV) and
per oral (PO) administration. The data showed very low blood
concentrations especially of 2, while 3 had high enough
blood concentrations to enable calculation of intravenous
pharmacokinetic parameters indicating a high steady state
volume of distribution (Vss) (Table 4, Fig. 2). Intending to
improve pharmacokinetic properties, we decided to explore
the possibility of modifying the C8-position of the central
fragment. In our previous structure–activity relationship
investigations, our focus was on ring-fused 2-pyridone
analogues with structural changes at the C7-, C6-, and C3-
positions, while the C8-cyclopropyl substituent remained
unmodified. In this study, we have instead synthesized and
evaluated a small library of C8-oxygen and nitrogen
analogues with the overall aim to maintain anti-Chlamydial
activity and improve oral availability. An earlier study10
showed that there was no discernable difference between the
two enantiomers of compound 24 and therefore all
compounds presented here were prepared and tested as
racemic mixtures.
Results & discussion
By introducing heteroatom containing substituents in the C8-
position we aimed to reduce the lipophilicity and improve
the drug-like properties of the compounds. First a set of C8-
Fig. 1 Chemical structures of compounds 1, 2, and 3.
Fig. 2 Blood concentration versus time of 3 (1.2 mg kg−1), 18 (0.9 mg
kg−1), and 30 (1.0 mg kg−1 IV, 10 mg kg−1 PO). Error bars indicate SEM.
Scheme 1 Synthesis of C8-methoxy amide analogues 5–7. Reagents and conditions: a) aniline or 4-methylaniline, propylphosphonic anhydride
(50% in EtOAc), pyridine, MeCN/EtOAc (1 : 1), −10 °C to rt, 24–43 h, 5: 58%, 6: 38%; b) NaNO2, TFA, DCM, O2 atmosphere, rt, 1–7 h; c) activated Zn
dust, AcOH, rt, 31–48 h, 8: 30% over two steps; 9: 35% over two steps; d) BBr3, DCM, −40 °C to rt, 6 h, 10%.
MedChemComm Research Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 6
/1
8/
20
20
 4
:0
3:
44
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1968 | Med. Chem. Commun., 2019, 10, 1966–1987 This journal is © The Royal Society of Chemistry 2019
hydroxyl or -methoxy substituted analogues were designed
and for these the previously published carboxylic acid 4 (ref.
13) served as a key intermediate (Scheme 1). In our previous
study10 the phenyl amide and p-methyl phenyl amide at the
C3-position gave similar biological results. We therefore
prepared C8-methoxy, C3-amide analogues 5 and 6 by amide
coupling under basic conditions with the corresponding
amine and propylphosphonic anhydride as coupling
reagent.14 C3-Phenyl amide 7 was generated by demethylation
of analogue 5 with boron tribromide (Scheme 1). Nitration
and subsequent reduction with zinc in acetic acid15 starting
from amides 5 and 6 gave the desired C6-amines 8 and 9
(Scheme 1).
The previously observed potency of 3 (Fig. 1) also
motivated us to synthesize the 1,2,3-triazole analogue. Thus,
the carboxylic acid intermediate 4 underwent Curtius
rearrangement in tert-butyl alcohol to acquire the BOC-
protected amine 10, which upon acidic deprotection resulted
in the primary amine 11 (Scheme 2). The final 1,2,3-triazole
12 was obtained by diazo transfer followed by CuĲI)-catalyzed
azide–alkyne cycloaddition (CuAAC) (Scheme 2).
Our previous study also revealed that the 1-naphthyl
substituent could be exchanged for a 2,3-dimethyl phenyl
substituent without loss of potency.10 This C7-substituent was
incorporated into the ring-fused 2-pyridone scaffold using
2,3-dimethyl phenyl substituted Meldrum's acid 14 to give
ring-fused 2-pyridone 15 (Scheme 3). The three C3-amides
(16, 17, and 18) were obtained through methyl ester
hydrolysis and then subsequent amide coupling of the
generated acid using the corresponding aniline derivative.
We have previously prepared and tested 1,2,4-oxadiazole
substituted compounds which are easily accessible directly
from the corresponding carboxylic acids.11 To further
evaluate these moieties together with other C7- and C8-
substituents we prepared two more of these amide isosteres
via hydrolysis of methyl ester 15 and then amide coupling
with benzamide oxime and TBTU followed by cyclization16 to
generate the 1,2,4-oxadiazole 19. These analogues were C6-
aminated via the established nitration-reduction route
resulting in four C6-amine analogues 20, 21, 22, and 23
(Scheme 3).
The fourteen C8-oxygen analogues were evaluated for their
ability to inhibit C. trachomatis infectivity by the previously
described reinfect assay (Table 1). Reinfect values show
inhibition of Chlamydia infectivity by the tested compound in
relation to DMSO treated control infections.10,11 The reinfect
Scheme 2 Synthesis of C8-methoxy 1,2,3-triazole 12. Reagents and conditions: a) DPPA, Et3N, t-BuOH, 2 h, 85 °C, 60%; b) TFA, DCM, 2 h, rt, 32%; c)
imidazole-1-sulfonyl azide H2SO4, CuSO4, K2CO3, MeOH, 40 h, 50 °C; d) phenyl acetylene, CuSO4, sodium ascorbate, DMF, H2O, rt, 4 h, 4% from 11.
Scheme 3 Synthesis of C8-methoxy analogues 16–23 with a C7-2,3-dimethyl phenyl substituent. Reagents and conditions: a) TFA, DCE, MWI, 120
°C, 3 min, 80%; b) 1 M LiOH(aq), THF, rt, 15 h; c) for 16 and 17: aniline, 4-methylaniline, propylphosphonic anhydride (50% in EtOAc), pyridine,
MeCN/EtOAc (1 : 1), −10 °C to rt, 24 h, 16: 82%, 17: 39%; for 18: 3-fluoro-5-methylaniline, HATU, DIPEA, DCM, 2 h, 95%; d) NaNO2, TFA, DCM, O2
atmosphere, rt, 2.5–6 h; e) activated Zn dust, AcOH, rt, 20–23 h, 21: 30%, 22: 17%, 23: 38% over two steps; f) 1 M LiOH(aq), THF, rt, 15 h; g)
benzamidoxime, TBTU, DIPEA, DMF, MWI, 170 °C,12 min, 46%; h) NaNO2, TFA, DCM, O2 atmosphere, rt, 1 h; i) activated Zn dust, AcOH, rt, 19 h,
60%.
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assay is cell based and also provides preliminary information
about the abilities of the compounds to penetrate biological
membranes, attach to their target and exert their function on
the intracellular bacteria. In brief, HeLa cells infected with C.
trachomatis serovar L2 were treated with a compound (2.5
μM or 1 μM) and incubated for 48 h before Chlamydia was
harvested by cell lysis. The cell lysate was used to reinfect
fresh HeLa cells and the number of Chlamydia inclusion
forming units (IFU) formed during the reinfection were
enumerated after 48 hours incubation. The reinfect value is
the reduction in percent of IFUs in a compound treated
infection compared to DMSO treated controls. The
cytotoxicity of the compounds at 10 μM was tested in a
resazurin cell toxicity assay (HeLa cells) to assess that the
anti-chlamydial effect of the compounds was not due to host
cell toxicity.10,11
The C8-hydroxy (7) and -methoxy (5) analogues, both had
slightly lower calculated logP (ref. 17) value than the
previously reported cyclopropyl analogue 24,10 but proved
less active (Table 1). In addition, the synthesis of the hydroxyl
Table 1 C8-Oxygen analogues. Reinfect values indicate the % of inhibition of infectivity in the second cycle of infection at 2.5 μM or 1 μM. HeLa viability
values express the % of cell growth when treated with 10 μM of compounds. LogP is the logarithm of the partition coefficient between n-octanol and
water
ID R3 R6 R7 R8 Reinfect 2,5 μM (%) Reinfect 1 μM (%) HeLa viability 10 μM (%) Calculated logP (ref. 17)
24 H 87 ± 6 67 ± 8 100 ± 4a 5.4
2 NH2 98 ± 2 94 ± 5 101 ± 3
a 4.9
3 NH2 91 ± 4 90 ± 4 105 ± 4
a 5.1
7 H OH 21 ± 14 n.d. 93 ± 6 4.8
5 H OCH3 24 ± 8 n.d. 91 ± 6 5.0
8 NH2 25 ± 14 n.d. 94 ± 2 4.5
6 H OCH3 94 ± 0 62 ± 1 89 ± 4 5.3
9 NH2 51 ± 16 n.d. 91 ± 2 4.8
12 H OCH3 81 ± 9 n.d. 87 ± 3 5.2
16 H OCH3 51 ± 5 22 ± 2 89 ± 2 4.4
21 NH2 25 ± 14 n.d. 94 ± 1 3.9
17 H OCH3 98 ± 1 71 ± 4 88 ± 3 4.7
NH222 56 ± 13 n.d. 93 ± 1 4.2
18 H OCH3 95 ± 2 77 ± 4 90 ± 2 5.0
NH223 47 ± 16 n.d. 92 ± 2 4.4
19 H OCH3 1 ± 4 n.d. 91 ± 3 4.8
20 NH2 17 ± 8 n.d. 94 ± 2 4.3
n.d. not determined. a Data provided from previous studies.10,11
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analog required additional low yielding steps and therefore
we decided not to continue with this series. In previous
studies introduction of the C6-amine has been shown to
improve activity10,11 but the corresponding C6-amine
analogue 8 showed only 25% inhibition at 2.5 μM.
Exchanging the 1-naphthyl group to a 2,3-dimethyl phenyl
substituent at the C7-position resulted in a decreased log P
value as seen when comparing analogues 5 (5.0) and 13 (4.4),
together with a small improvement in potency. However, the
p-methyl phenyl amide 6 and the analogue 17 with a
2,3-dimethyl phenyl group at the C7-position demonstrated
comparable anti-infective activity to phenyl amide 24 at 2.5
μM. Unfortunately, their effect dropped at 1 μM to 62% and
71% inhibition respectively. A more promising result was
obtained with the 3-fluoro-5-methylaniline analogue 18,
although the potency at 1 μM was still lower than 2 and 3.
The 1,2,4-oxadiazole 19 and the 1,2,3-triazole 12 analogues
were evaluated but proved less active than analogue 2 and
the best C8 methoxy analogue 18. In contrast to previous
studies, introduction of a C6-amine gave little benefit with a
C8-methoxy substituent (Table 1). All the tested compounds
showed low toxicity towards HeLa cells at 10 μM.
A general drop in potency of the C8-oxygen analogues
compared with the cyclopropyl analogues was observed, with
all C8-oxygen compounds losing activity at concentrations
below 1 μM compared to the cyclopropyl analogues 2 and 3.
However, analogue 18 was one of the most potent among the
oxygen analogues and its synthesis in larger scale also proved
straightforward resulting in a crystalline product suitable for
various formulations. Therefore, this analogue was chosen
for further evaluation together with the previously identified
compounds 2 and 3. A formulation in lipid emulsion (for
details about the vehicle see the Experimental section)
enabled an oral dose of 10 mg kg−1. This formulation was
used in an in vivo pharmacokinetic evaluation (Table 4,
Fig. 2). Although the peak blood concentrations (Cmax) and
AUC of compound 18 were higher compared to compound 3
after the intravenous administration, the oral uptake was
unfortunately too low to allow for proper determination of
pharmacokinetic parameters after oral administration. The
concentrations of compound 2 after both intravenous and
oral administration were too low to allow calculation of
pharmacokinetic parameters. It was therefore clear that the
oral bioavailability of these compounds was extremely poor.
Scheme 4 A. Synthesis of C8-nitrogen analogues 26–30. B. Synthesis of C8-methyl sulfonamide C3-amide derivatives 32 and 33. Reagents and
conditions: a) CH3I, NaHCO3, DMF, 70 °C, 10 h; b) 1 M LiOH(aq), THF :MeOH (5 : 1), rt; c) aniline, HATU, DIPEA, DMF, 1 h, 55% from 25; d)
NaBHĲOAc)3, TFA, DCM, acetone, −15 °C to rt, overnight; e) 1 M LiOH(aq), THF :MeOH (4 : 1), rt, 1 h; f) suspended in DCM and dripped in to ethereal
HCl, −20 °C, overnight; g) aniline, HATU, DIPEA, DMF, 1 h, 43% from 25; h) methyl chloroformate, pyridine, DCM, rt, 2 h; i) 1 M LiOH(aq), THF :MeOH
(4 : 1), rt; j) aniline, HATU, DIPEA, DMF, 1 h, 38% from 25; k) methanesulfonyl chloride, pyridine, THF, rt, overnight; then: 1 M LiOH(aq), MeOH or THF :
MeOH (3 : 1), rt; l) aniline, HATU, DIPEA, DMF, 1 h, 30: 52% from 25; m) acetyl chloride, pyridine, DCM, rt, overnight; n) 1 M LiOH(aq), THF :MeOH
(5 : 1), rt, 2 h; o) aniline, HATU, DIPEA, DMF, 1 h, 50% from 25; p) 3-methylaniline or 3-fluoro-5-methylaniline, HATU, DIPEA, DMF, 4 h, 32: 49%, 33:
78%. The acid intermediates as isolated compounds are published previously.13
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We next considered that introduction of nitrogen based
C8-substituents would potentially have a greater influence on
drug-like properties. Therefore, a set of five analogues was
designed for evaluation. The previously published primary
amine intermediate 25 (ref. 13) served as the starting point
and a collection of five compounds with different C8-nitrogen
substituents were obtained (Scheme 4A). Methylation of the
C8-primary amine, hydrolysis of the C3-methyl ester and
following amide coupling using aniline resulted in
dimethylamine 27. The secondary amine 26 was obtained
through reductive alkylation of the C8-primary amine,
followed by ester hydrolysis and amide coupling. Compounds
28 and 29 were synthesized by reaction with methyl
chloroformate and acetyl chloride, respectively, followed by
C3-methyl ester hydrolysis and amide coupling. The final
methyl sulfonamide analogue was prepared by allowing the
C8-amine intermediate 25 to react with methane sulfonyl
chloride followed by hydrolysis and amide coupling using
aniline to generate the C8-methyl sulfonamide 30
(Scheme 4A). Evaluation of their biological activity again
showed a drop in potency compared to the cyclopropyl
analogues but both 27 and 30 showed about 90% inhibition
at 2.5 μM (Table 2). However, the calculated log P was
significantly lower for the methyl sulfonamide analogue 30
compared to the dimethylamine 27. To improve the potency
a set of four additional methyl sulfonamide analogues were
synthesized. Two of these were substituted phenyl amides (32
and 33, Scheme 4B and Table 2) chosen based on results of
our previous study10 and prepared by amide coupling from
the carboxylic acid 31.
In addition, two methyl sulfonamide analogues with C3-
amide isosteres instead of phenyl amides were synthesized.
The first of these two, the 1,2,4-triazole 38 easily accessible
from the corresponding methyl ester, was chosen based on
Table 2 C8-Nitrogen analogues. Reinfect values indicate the % of inhibition of infectivity in the second cycle of infection at 2.5 μM or 1 μM. HeLa
viability values express the % of cell growth when treated with 10 μM of compounds. LogP is the logarithm of the partition coefficient between
n-octanol and water
ID R3 R8 Reinfect 2.5 μM (%) Reinfect 1 μM (%) HeLa viability 10 μM (%) Calculated logP (ref. 17)
26 79 ± 9 25 ± 4 91 ± 4 5.5
27 94 ± 0 78 ± 20 92 ± 3 5.0
28a 12 ± 15 −19 ± 21 88 ± 3 4.6
29a 3 ± 9 44 ± 47 90 ± 5 4.4
30 89 ± 4 23 ± 12 94 ± 2 4.2
32 6 ± 17 6 ± 6 91 ± 2 4.7
33 −2 ± 5 n.d. 92 ± 2 4.5
38 20 ± 4 n.d. 93 ± 1 4.7
46 88 ± 7 n.d. 91 ± 0 4.3
n.d. not determined. a Variability observed between experimental replicates was a sign of low compound solubility.
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results from our previous study11 and obtained as described
in Scheme 5. A one-pot reaction18 was performed on the
N-carboxybenzyl (Cbz) protected methyl ester 36 to give the
1,2,4-triazole 37. The desired methyl sulfonamide 38 was then
prepared by acidic Cbz-deprotection followed by installment
of the methyl sulfonamide functionality via a reaction with
methane sulfonyl chloride (Scheme 5).
Earlier studies showed that the 1,2,3-triazoles were the
most potent amide bioisosteres and the 1,2,3-triazole 3 has
previously successfully been obtained via diazo transfer with
imidazole-1-sulfonyl-azide of the C3-primary amine.11
However, with a N-carboxybenzyl-protected amine at the C8-
position, the diazo transfer reaction proved unsuccessful and
was exchanged for a phthalimide as protecting group instead.
The phthalimide substituted thiazoline derivative 40 was
synthesized from 2-(1,3-dioxoisoindolin-2-yl)acetonitrile via
the ethyl imidate 39 (Scheme 6). The ring-fused 2-pyridone
methyl ester 41 was then obtained from 40 and 35 after 4
days at 80 °C and the following hydrolysis and re-closure of
phthalimide gave the carboxylic acid 42. The BOC-protected
43 was generated by Curtius rearrangement in tert-butyl
alcohol of intermediate 42 and subsequent acidic
deprotection of 43 resulted in the C3-amine 44. Diazo transfer
of intermediate 44 using imidazole-1-sulfonyl azide followed
CuĲI)-catalyzed azide–alkyne cycloaddition (CuAAC) with
phenyl acetylene resulted in the 1,2,3-triazole 45. The final
compound 46 was obtained via deprotection, followed by
reaction with methane sulfonyl chloride to generate the C8-
methyl sulfonamide moiety.
The four additional methyl sulfonamide analogues were
evaluated in the cell-based infection assay but none of the
new analogues showed any improvement compared to
compound 30. Since the activity of 30 was still in the low μM
range, with low toxicity and a lower calculated logP
compared to the analogues previously evaluated for
pharmacokinetic properties, the methyl sulfonamide 30 was
chosen together with analogues 3 and 18 for in vitro ADME
determination (Table 3). Compounds 3 and 18 showed
similar properties: very low solubility; low to moderate
permeability with low or no efflux and low metabolic stability
in both human and mouse liver microsomes (HLM, MLM).
Analogue 30 on the other hand distinguished itself from 3
Scheme 5 Synthesis of C8-methyl sulfonamide 1,2,4-triazole 38. Reagents and conditions: a) 35, TFA, DCM, 70 °C, 20 h, 85%; b) 1 M LiOH(aq),
THF, rt, 2 h; c) benzamidine·HCl, HATU, DIPEA, DMF, 3.5 h; then (4-methoxybenzyl)hydrazine·HCl, AcOH, 80 °C, 20 h; d) TFA, DCM, 50 °C, 22 h,
39% from 36; e) 33% HBr/AcOH, DCM, rt, 2 h; f) methane sulfonyl chloride, pyridine, rt, 18 h; then: 1 M LiOH(aq), THF :MeOH (3 : 1), rt, 53% from 37.
Scheme 6 Synthesis of C8-methyl sulfonamide 1,2,3-triazole 46. Reagents and conditions: a) AcCl, EtOH/EtOAc (1 : 1), 0 °C to rt, 17 h, (see
procedure); b) L-cysteine methyl ester·HCl, Et3N, DCM, rt, 3 days, 64%; c) 35, TFA, DCM, 80 °C, 4 days, 62%; d) 1 M LiOH(aq), THF, rt, 4 h; e) AcOH,
DMF, 150 °C, 20 h, 78% from 41; f) DPPA, Et3N, t-BuOH, 2 h, 85 °C, 57%; g) TFA, DCM, rt, 2 h, 88%, h) imidazole-1-sulfonyl azide·H2SO4, CuSO4,
K2CO3, MeOH, 24 h, 50 °C; i) phenyl acetylene, CuSO4, sodium ascorbate, DMF, H2O, rt, 3.5 h, 1% from 44; j) methyl amine, EtOH, rt, 20 h; k)
methanesulfonyl chloride, pyridine, rt, 26 h; then: 1 M LiOH(aq), THF :MeOH (3 : 1), rt, 2 h, 99% from 45.
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and 18 by improved solubility, much higher permeability and
higher metabolic stability in both species. The mouse plasma
protein binding was high, especially for analogues 3 and 18,
which influences scaling (static well-stirred model) to hepatic
clearance (CL) when using the plasma protein binding as a
surrogate for the whole blood free fraction. Another
limitation is that the blood to plasma ratio for these
compounds are unknown, and it is known that in particular
for high CL molecules the impact of the blood to plasma
ratio may be large for these extrapolations.19 Thus, due to the
high protein binding, the predicted unbound hepatic
extraction (Eu) in mouse was low (Table 3).
An in vivo pharmacokinetic validation to investigate the
in vitro–in vivo correlation was then performed. The
compounds were administered both intravenously and orally
with the same formulation as previously used. The oral data
for compound 3 and 18 was too low to be able to be
quantified, therefore only intravenous is shown (Table 4,
Fig. 2). Interestingly, a remarkable improvement was
observed for analogue 30 compared to 3, 18 and the earlier
evaluated candidates. Compound 30 yielded oral blood
concentrations in the μM range, lower CL and an oral
bioavailability of 41%. Analogue 18 showed very low AUC in
comparison to 3 despite the similarity in in vitro ADME
properties and it is likely that the increased membrane
permeation contributed to the higher CL of compound 3. In
comparison to the obtained in vitro data, the predicted CL is
underestimated indicating erroneous assumptions in models
or large extrahepatic contributions. Taken together,
incorporation of a sulfonamide contributes to a lowered CL
in vitro and in vivo, resulting in a longer in vivo half-life (t1/2).
Further, the sulfonamide effectively shifted compound 30
into a Biopharmaceutical Classification System (BCS)
category II compound (high permeability, low solubility),
while compounds 3 and 18 were categorized as class IV
compounds (low permeability, low solubility), which are
difficult to handle in further drug development.
With these encouraging results in hand, a first treatment
study was conducted. Although the solubility had improved
slightly it was not possible to dissolve analogue 30 in the
vehicle at a higher dose than 10 mg kg−1, which was given
twice a day via oral gavage to nine C. trachomatis-infected
mice. As a control, vehicle without active compound was
given to nine mice, while six mice received doxycycline. The
mice showed no negative vital signs from the treatment, but
unfortunately the course of infection was not improved at
this dose (Fig. 3).
The pharmacokinetic improvements observed represent a
great advance towards a proof of concept for an orally available
drug to treat C. trachomatis infection. The finding that C8-
methyl sulfonamides so strongly can influence important
pharmacokinetic parameters in favor of oral administration is
an important step forward. Although no treatment effect was
observed at the tested dose, the compounds show very low
toxicity and therefore higher doses of the active compound
could be utilized in future trials. To accomplish this, improved
vehicles will be required to deliver these analogues in higher
dose. In parallel, additional fine tuning of the substitution
pattern to improve the potency while retaining the important
pharmacokinetic properties observed with the methyl
sulfonamide 30 is ongoing in our laboratories.
Materials and methods
Biology
Cell culture and chlamydia propagation. HeLa 229 cells
(CCL-2.1; ATCC) were cultured at 37 °C (5% CO2) in RPMI-
1640 medium (HyClone) with 25 mM HEPES and 2 mM L-
Table 4 In vivo mouse pharmacokinetics of compounds 3, 15 and 30.
C0/Cmax: maximal measured plasma concentration; Tmax: time of C0/
Cmax; AUC: calculated area under the curve, extrapolated to infinity; t1/2:
elimination half-life; CL: clearance; Vss: volume of distribution at steady
state; F: bioavailability
3 18 30 30
Administration IV IV IV PO
Dose (mg kg−1)a 1.2 0.90 1.0 10
C0/Cmax (MM) 0.040 0.41 1.7 3.7
Tmax (h) — — — 1
AUC0−∞ (μM × h) 0.10 ± 0.01 0.95 ± 0.28 4.8 ± 0.4 20.3 ± 4.5
t1/2 (h) 3.7 1.2 5.3 2.6
CL (L h−1) 0.51 ± 0.05 0.040 ± 0.01 0.010 ± 0.001 —
Vss (L kg
−1) 27 ± 22 1.1 ± 0.6 0.62 ± 0.16 —
F (%) — — — 41
a Variability in the compounds dose was caused by the different
weight of mice between experiments.
Table 3 In vitro ADME properties of 3, 18 and 30
Assay 3 18 30
Solubility (μM ± SD) 0.31 ± 0.16 0.32 ± 0.04 1.3 ± 0.8
Caco-2 A-B Papp
(×106 cm s−1 ± SD)
0.33 ± 0.05 2.1 ± 0.04 30 ± 2.6
Caco-2 efflux ratio 0.6 3.2 2.0
Mouse plasma protein binding
(fraction unbound, %)
<0.1 0.1 0.39
Intrinsic clearance
(HLM, μl min−1 mg−1)
187 184 39
Intrinsic clearance
(MLM, μl min−1 mg−1)
135 440 59
Eu (mouse unbound hepatic extraction) 0.01 0.09 0.001
MedChemComm Research Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 6
/1
8/
20
20
 4
:0
3:
44
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1974 | Med. Chem. Commun., 2019, 10, 1966–1987 This journal is © The Royal Society of Chemistry 2019
glutamine, supplemented with 10% fetal bovine serum (FBS)
(Sigma) and 10 μg mL−1 gentamicin. For the resazurin
cytotoxicity experiments, colorless DMEM (Gibco)
supplemented with 10% FBS (Sigma) was used. Chlamydia
trachomatis serovar L2 454/Bu (VR902B; ATCC) was cultured
in HeLa cells. EB stocks of C. trachomatis were purified as
described by Caldwell et al. and stored at −80 °C in SPG
buffer (0.25 M sucrose, 10 mM sodium phosphate and 5 mM
L-glutamic acid).20
Reinfect assay. Reinfection experiments were performed
as previously described.10 C. trachomatis serovar L2 EBs were
mixed with Hank balanced salt solution (HBSS) and used to
infect HeLa cells at a MOI of 0.3–0.5. After 1 h, the
compounds were added mixed with RPMI at 2.5 μM or 1 μM.
The cells were incubated for 44–48 h, then cold Milli-Q water
was added in order to osmotically lyse the cells and harvest
the EBs. 4× SPG was added to the EBs on MQ water to reach
1× SPG, and 10-fold serial dilutions were performed in HBSS.
Fresh HeLa cells were infected with the diluted EBs,
substituting the HBSS by fresh RPMI medium 1 h post
infection. Cells were incubated for 44–46 h before fixation
with methanol. Inclusions were stained with in-house rabbit
anti-Chlamydia antibodies21 (1 : 1000), followed by secondary
donkey anti-rabbit FITC-labeled antibody (1 : 1000) (Jackson
ImmunoResearch). Cell nuclei were stained with DAPI (1 :
1000). Infected cells were observed and measured by
Arrayscan automated microscopy (ArrayScan VTI HCS,
Thermo Scientific). Reinfect value was calculated as the
percentage of IFUs compared to a DMSO treated control. The
presented value is the average of three independent
experiments with duplicates for each condition.
Resazurin cytotoxicity assay. HeLa cells were seeded in 96
well plates, leaving the outer wells filled with PBS to prevent
edge effects. Compounds were tested at 10 μM in DMEM with
0.5% DMSO. Incubation proceeded for 48 h, whereafter 10 μL
of resazurin (400 μM) was added to each well followed by 3 h
incubation at 37 °C, 5% CO2 in the dark. After that,
fluorescence in the wells was analyzed by Tecan Safire plate
reader (excitation 535 nm, emission 595 nm). The results were
calculated as the average from triplicate compound treated
wells in percent of a DMSO treated control in Graph Pad Prism.
Compound formulation for in vivo administration. For
intravenous administration, the compound was dissolved in
DMSO and diluted to 1 mM corresponding to 0.45–0.51 mg
mL−1 compound in PBS with 10% cremophor, 5% EtOH and
4% DMSO. For oral administration the compound was
dissolved in a lipid vehicle containing 55% capmul, 15%
akomed, 15% etanol and 15% cremophor that was vigorously
mixed with lukewarm water to form an emulsion. The final
concentration in the oral dose solutions was 2.24 mg mL−1
compound, 6.8% capmul, 1.9% akomed, 1.9% cremophor,
1.9% EtOH in H2O.
In vitro ADME determination. All quantitative analyses
were performed using liquid chromatography tandem mass
Fig. 3 Oral treatment with compound 30 did not affect vaginal C. trachomatis infection in mice. The number of C. trachomatis IFUs per vaginal
swab over time during the 7 days treatment and afterwards. C3H/HeJ mice were vaginally infected with C. trachomatis and treated with 10 mg
kg−1 of compound 30, vehicle alone or 2 mg kg−1 doxycycline.
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spectrometry (LC-MS/MS) on a Sciex QTRAP 6500 or a Waters
XEVO TQ triple quadrupole mass spectrometer coupled to a
Waters Acquity ultra-performance liquid chromatography
(UPLC). Mobile phases (A): 0.1% formic acid, (B): 0.1%
formic acid in acetonitrile were used with column HSS T3 50
× 2 mm and runtime was 2 minutes.
The thermodynamic solubility assay utilized solid weighed
compound (0.2–0.5 mg) in a HPLC vial and PBS was added to
yield a saturated solution. The vial was sealed and shaken
(900 rpm) at room temperature for 48 h. After the incubation
the suspension was transferred to conical glass inserts and
centrifuged for 30 min at 10 000×g, at 23 °C. The supernatant
was then diluted in acetonitrile/H2O (50/50) 10–1000× for LC-
MS/MS analysis, in two steps.
The Caco-2 study was performed in accordance with
published protocols.22 Caco-2 cell monolayers (passage 94–
105) were grown on permeable filter support and used for
transport study on day 21 after seeding. Prior to the
experiment a drug solution of 1 μM was prepared and
warmed to 37 °C. The Caco-2 filters were washed with pre-
warmed HBSS prior to the experiment, and thereafter the
experiment was started by applying the donor solution on the
apical or basolateral side. The transport experiments were
carried out at pH 7.4 in both the apical and basolateral
chamber. The experiments were performed at 37 °C and with
a stirring rate of 500 rpm. The receiver compartment was
sampled at 15, 30 and 60 minutes, and at 60 minutes also a
final sample from the donor chamber was taken in order to
calculate the mass balance of the compound. The samples
(100 μl) were transferred to a 96-well plate containing 100 μl
acetonitrile and Warfarin as internal standard and was sealed
until LC-MS/MS analysis.
The metabolic stability assay was determined in 0.5 mg
ml−1 human or animal liver microsomes (XenoTech LLC, KS,
USA) at a compound concentration of 1 μM in 100 mM
phosphate buffer pH 7.4 in a total incubation volume of 500
μl. The reaction was initiated by addition of 1 mM NADPH
(final concentration). At various incubation times, i.e. at 0, 5,
10, 20, 40 and 60 min, a sample was withdrawn from the
incubation and the reaction was terminated by addition to
1.5 volumes of cold acetonitrile. After centrifugation the
supernatant was analyzed for the amount of parent
compound remaining by LC-MS/MS. To determine the
in vitro half-life, the percent remaining compound (analyte
area/IS area) was calculated using time 0 min sample as
100%. The natural logarithm of the % remaining compound
was plotted against time followed by linear regression.25
The plasma protein binding assay utilized rapid
equilibrium dialysis (RED, Thermo Scientific Inc., USA)
device inserts which allow for short dialysis times (2–4 h) as
compared to traditional methods (>8 h) and minimal drug
consumption in a 96-well format. Pooled human plasma
with citric acid as anti-coagulant from two healthy non-
smoking blood donors was provided by Uppsala Academic
Hospital. Human plasma was obtained from volunteered,
healthy, regular blood donors and no ethical improvement
was required. Informed consent was obtained from human
donors. Plasma from CD-1 mice with EDTA or Heparin as
anti-coagulant was purchased from Novakemi AB, Sweden.
In brief, 0.2 ml 10% plasma, 90% isotonic buffer test
solution was spiked 10 μM compound and 1% final DMSO
concentration and transferred to the membrane tube in the
RED insert. 0.35 ml isotonic phosphate buffer pH 7.4 was
added to the other side of the membrane. The 96-well base
plate was then sealed with an adhesive aluminum foil film
to prevent evaporation. The sample was incubated with
rapid rotation (900 rpm) on a Kisker rotational incubator
(Kisker Biotech Gmbh & Co. KG, Germany) at 37 °C for 4 h
to achieve equilibrium. A stability test of the test solution
was also prepared to allow detection of drug degradation,
100 μL of the spiked plasma test solution (in a plastic vial
or on a sealed plate) was incubated at 37 °C for 4 h (or as
long as the dialysis time). The plasma test solution was
frozen directly after the administration to prevent any
degradation. Prior to LC-MS/MS analysis the plasma and
buffer sample were treated with the addition of methanol
(1 : 3) containing Warfarin as analytical internal standard to
precipitate proteins. The standard curve was created using
the previously frozen plasma standard. The volume in each
well consisted of 25 μl plasma and 25 μl buffer to minimize
any matrix related effects in interpretation. The plate was
then sealed, centrifuged and the supernatant was analyzed
by mass spectrometry (LC-MS/MS). To adjust the fraction
unbound (fu) for the diluted plasma the following equation
was used: undiluted fu = 1/DF/{[(1/fu) − 1] + 1/DF}, DF =
dilution factor.23
Pharmacokinetics in mice. Compounds were administered
to mice either intravenously (IV) by a 50 μL tail vein injection
or orally (PO) by a 100 μL oral gavage. Three mice per dose
and route of administrations were used and the doses are
indicated in Table 4. Compound 30 was given to 9 week old
females C3H/HeOuJ (JAX stock #000635, Charles River,
Germany), compounds 15 and 3 were given to 22-week-old
females C3H/HeJ (JAX stock #000659, The Jackson laboratory,
USA). Blood samples were collected from the tail vein at 10
minutes after intravenous administration and at 0.5, 1, 2, 4,
8, and 24 hours after both IV and PO administration using
lithium heparin coated capillary blood collection tubes
(Microvette CB300LH, Sarstedt, Nümbrecht, Germany).
Twenty μL blood was mixed with 40 μL acetonitrile and
stored at −20 °C until analysis. Whole blood samples were
further diluted to 200 μl and dose solutions were diluted 500
times in acetonitrile/H2O (60/40) and extracted by addition of
ice-cold methanol (1 : 4) followed by centrifugation at 3500
rpm prior to analysis. Standard curves were constructed
using blank mouse blood matrix spiked with compound from
10 mM DMSO stocks. Calculations of non-compartmental
pharmacokinetic properties utilized Microsoft Excel and
Graphpad Prism 7. Errors are standard deviations of the AUC
and nonlinear regression fitting.
Animal experiments were performed according with the
Guidelines for Care and Use of Laboratory Animals of Umeå
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University and approved by Umeå Animal Research Ethical
Committee, the Swedish Board of Agriculture (A4-14, A75-15).
C. trachomatis in vivo infection model. Eight week old
female C3H/HeJ mice (JAX stock #000659, The Jackson
laboratory, USA) were injected subcutaneously with 2.4 mg of
medroxiprogesteron acetate (Pfizer) 10 and 3 days prior to
infection to synchronize their estrous cycles. A pediatric
nylon flocked swab (Copan, Italia) pre-wet in SPG was used
to remove vaginal mucus prior to intravaginal injection of
5000 CFU C. trachomatis serovar D (VR-885, ATCC) in 10 μL
SPG. Mice were placed in an inverted position during 30
minutes under midazolam/ketamine anesthesia to allow the
inoculum to gravitate to the uterine cervix. Treatment by oral
gavage was initiated 10 hours after infection and repeated
every 12 hours for 7 days. Nine mice were given 100 μL 2.33
mg mL−1 of compound 30 in a water emulsion containing
6.8% capmul, 1.9% akomed, 1.9% cremophor and 1.9%
EtOH. Another nine mice received 100 μL of the same
formulation without compound 30 and six mice were given
100 μL 2 mg mL−1 doxycycline in water. Day 2, 4, 7, 11, 14
and 21 after infection, vaginal swab samples were obtained
by rotating a SPG-wet pediatric nylon flocked swab
intravaginally during 10 seconds. Each swab was transported
in a micro centrifuge tube with 200 μL ice cold SPG and
vigorously vortexed prior to dilution of the SPG with HBSS 1 :
2, 1 : 20, 1 : 200 and 1 : 2000. Thirty μL of vaginal swab
dilution was inoculated in duplicates in a 96 well plate with
20 000 HeLa cells per well. The plate was centrifuged at 900×g
for 1 h at 37 °C. The inoculum was replaced by 100 μL
preheated RPMI supplemented as above and with gentamicin
(10 μg mL−1) per well and incubated for 42–46 h prior to
methanol fixation, immunostaining and Chlamydia CFU
quantification by Array Scan as described above.
Comp logP
Computed log P values were calculated in MOE.17
Chemistry
General. All reagents and solvents were used as received
from commercial suppliers, unless indicated otherwise.
Triethylamine, N,N-diisopropylethylamine and pyridine were
passed through activated alumina oxide and stored over
activated 3 Å molecular sieves prior to use. Anhydrous
solvents (THF, DMF, Et2O and DCM) were obtained from a
solvent drying system and collected fresh prior to every
reaction. All reactions were carried out in oven dried
glassware and under a nitrogen atmosphere. TLC was
performed on aluminum backed silica gel plates (median
pore size 60 Å) and detected with UV light at 254 nm.
Column chromatography was performed using silica gel with
average particle diameter 50 μM (range 40–65 μM, pore
diameter 53 Å) and eluents are given in brackets. Optical
rotations were measured at 589 nm on a Polarimeter Autopol
IV (Rudolph Research Analytical) at 20 °C and concentrations
are given as g mL−1. High resolution mass spectra (HRMS)
data was performed using a mass spectrometer, an Agilent
1290 binary LC System connected to a Agilent 6230 Accurate-
Mass TOF LC/MS (ESI+); calibrated with Agilent G1969-85001
ES-TOF Reference Mix containing ammonium
trifluoroacetate, purine and hexakisĲ1H,1H,3H-
tetrafluoropropoxy)phosphazine in 90 : 10 MeCN :H2O. HPLC
purifications were performed on a system (Gilson) equipped
with a 250 × 21.5 mm Nucleodur® C18 HTEC (particle size 5
μM) column using a flow rate of 18–20 mL min−1 and
detection at 214 nm. 1H and 13C NMR spectra were recorded
on a Bruker Avance III 400 MHz or a Bruker Avance III HD
600 MHz spectrometer at 298 K unless otherwise stated and
calibrated by using the residual peak of the solvent as the
internal standard (CDCl3: δH = 7.26 ppm; δC = 77.16 ppm;
DMSO-d6: δH = 2.50 ppm; δC = 39.52 ppm; CD3OD: δH = 3.31
ppm; δC = 49.00 ppm).
19F NMR spectra were recorded with
proton decoupling on a 400 MHz spectrometer at 298 K with
CF3CO2H as an internal standard (δF = −76.5 ppm). The
asterisk * indicates peaks determined with two-dimensional
proton–carbon correlation techniques (HSQC and HMBC),
which were used to supplement and complete the 13C NMR
spectra where signals were otherwise broadened or weak.
Amide coupling reactions with propylphosphonic anhydride
(T3P) were prepared by adaptation of the procedure reported
by Dunetz et al.14 The following compounds were synthesized
and characterized as described previously: 1,9 2,10 3,11 4,13
13, 14, 24,10 25,13 31,13 34,13 35.24
Experimental
8-Methoxy-7-(naphthalen-1-ylmethyl)-5-oxo-N-phenyl-2,3-
dihydrothiazolo[3,2-a]pyridine-3-carboxamide (5). The
carboxylic acid 4 (191 mg, 0.520 mmol) was suspended in
anhydrous MeCN/EtOAc (1 : 1, 6 mL) and after cooling the
suspension to ≃10 °C (NaCl/ice), pyridine (130 μL, 1.61
mmol) was added. The reaction mixture was stirred for 5
min, and aniline (71 μL, 0.79 mmol) was added, followed by
dropwise addition of T3P (50% in EtOAc; 0.62 mL, 1.0 mmol).
The reaction was stirred for 3 h, then allowed to warm to
room temperature and stirred for 16.5 h. Additional aniline
(36 μL, 0.40 mmol) was added and after 45 min additional
pyridine (42 μL, 0.52 mmol) was added and stirred at room
temperature for 23 h. The reaction mixture was cooled to 0
°C, quenched with 1 M HCl(aq) and extracted with DCM (×3).
The organic extracts were washed successively with water and
brine, dried (Na2SO4) and the solvent removed under reduced
pressure. Purification by flash chromatography (SiO2, 15–
100% EtOAc in heptane) and freeze-drying from H2O :MeCN
(6 : 1) afforded the amide 5 as a white powder (134 mg, 58%).
1H-NMR (400 MHz, CDCl3) δ 10.35 (s, 1H), 7.91–7.79 (m, 3H),
7.52–7.41 (m, 5H), 7.37–7.32 (m, 1H), 7.24–7.17 (m, 2H),
7.06–6.99 (m, 1H), 5.78–5.74 (m, 1H), 5.71–5.66 (m, 1H), 4.36,
4.22 (ABq, JAB = 17.0 Hz, 2H), 4.04–3.97 (m, 1H), 3.77 (s, 3H),
3.54 (dd, J = 8.2, 11.4 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ
164.7, 161.3, 152.3, 140.5, 137.9, 137.8, 134.0, 133.1, 131.8,
128.9, 128.8, 128.04, 128.02, 126.5, 125.9, 125.6, 124.2, 123.8,
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119.8, 114.4, 65.1, 60.8, 32.7, 30.5. HRMS (ESI+) (m/z): [M +
H+]+ calcd. for C26H23N2O3S, 443.1423; found, 443.1432.
8-Methoxy-7-(naphthalen-1-ylmethyl)-5-oxo-N-(p-tolyl)-2,3-
dihydrothiazolo[3,2-a]pyridine-3-carboxamide (6). Carboxylic
acid 4 (195 mg, 0.530 mmol) was suspended in anhydrous
MeCN/EtOAc (1 : 1, 6 mL) and after cooling the suspension to
≃10 °C (NaCl/ice), pyridine (130 μL, 1.61 mmol) was added.
After stirring for 5 min, p-methylaniline (70 mg, 0.65 mmol)
was added, followed by dropwise addition of T3P (50% in
EtOAc; 0.63 mL, 1.1 mmol). Stirred at −10 °C for 3 h and then
allowed to return to rt and stirred for 16.5 h. Additional
p-methylaniline (47 mg, 0.44 mmol) was added and stirred
for 45 min and then pyridine (42 μL, 0.52 mmol) was added
and stirred for another 4 h. The reaction mixture was cooled
to 0 °C and quenched with 1 M HCl(aq) (10 mL), diluted with
EtOAc and extracted with EtOAc (×3). The combined organic
layers were washed successively with water and brine, then
the precipitate was filtered off and the filtrate was dried
(Na2SO4) and concentrated under reduced pressure.
Purification by flash chromatography (SiO2, 30–100% EtOAc
in heptane) and freeze-drying from H2O :MeCN (6 : 1)
afforded the amide 6 as a white powder (107 mg, 44%). 1H-
NMR (400 MHz, CDCl3) δ 10.23 (s, 1H), 7.91–7.77 (m, 3H),
7.51–7.37 (m, 5H), 7.36–7.32 (m, 1H), 7.08–7.03 (m, 2H),
5.79–5.77 (m, 1H), 5.73 (d, J = 7.9 Hz, 1H), 4.40–4.17 (m, 3H),
3.76 (s, 3H), 3.62 (dd, J = 7.9, 11.2 Hz, 1H), 2.28 (s, 3H). 13C-
NMR (100 MHz, CDCl3) δ 164.3, 161.5, 152.3, 140.3, 138.1,
135.4, 134.1, 134.0, 133.1, 131.9, 129.5, 129.0, 128.12, 128.07,
126.6, 126.0, 125.6, 123.9, 119.9, 114.8, 65.2, 60.9, 32.8, 30.3,
21.0. HRMS (ESI+) (m/z): [M + H+]+ calcd. for C27H25N2O3S,
457.1579; found, 457.1590.
8-Hydroxy-7-(naphthalen-1-ylmethyl)-5-oxo-N-phenyl-2,3-
dihydrothiazolo[3,2-a]pyridine-3-carboxamide (7). BBr3 (0.035
mL, 0.020 mmol) was added slowly to a stirred solution of
amide 5 (150 mg, 0.339 mmol) in DCM (5 mL) at −40 °C (dry
ice/acetone) and was stirred for 6 h, meanwhile the reaction
mixture was allowed to return to rt. The reaction mixture was
quenched with NaHCO3 and then diluted with EtOAc. The
aqueous layer was extracted with EtOAc (×2, 1 M HCl(aq) was
added to acidify the aqueous layer). The combined organic
layers were washed with brine, dried (Na2SO4) and the drying
agent was filtered off. The drying agent (Na2SO4) was stirred
in EtOAc (200 mL) for 1 h, then it was filtered off and the
combined organic layers were concentrated under reduced
pressure to obtain the crude product (45.6 mg). Purification
by HPLC (H2O/MeCN, 0.75% formic acid, 30–100% MeCN, 25
min, 214 nm) and freeze-drying from H2O :MeCN afforded
the amide 7 as a white powder (5.8 mg). A white precipitate
in the combined aqueous layers was filtered off and after
freeze-drying from H2O :MeCN afforded the amide 7 (8.0
mg). The total yield of the reaction: 14 mg, 10%. 1H-NMR
(400 MHz, DMSO-d6) δ 10.39 (s, 1H), 8.56 (s, 1H), 8.00–7.84
(m, 3H), 7.59–7.47 (m, 5H), 7.42 (d, J = 6.9 Hz, 1H), 7.35–7.26
(m, 2H), 7.10–7.01 (m, 1H), 5.50–5.44 (m, 1H), 5.27 (s, 1H),
4.32, 4.23 (ABq, JAB = 16.8 Hz, 2H), 3.91 (dd, J = 11.8, 9.0 Hz,
1H), 3.62–3.54 (m, 1H). 13C-NMR (100 MHz, DMSO-d6) δ
166.0, 158.7, 149.8, 138.7, 136.2, 134.3, 133.5, 131.5, 131.4,
128.8, 128.6, 127.6, 127.3, 126.3, 125.8, 125.7, 124.0, 123.6,
119.0, 112.7, 64.3, 32.4, 32.2. HRMS (ESI+) (m/z): [M + Na+]+
calcd. for C25H21N2O3S, 429.1267; found, 429.1269.
6-Amino-8-methoxy-7-(naphthalen-1-ylmethyl)-5-oxo-N-
phenyl-2,3-dihydrothiazolo[3,2-a]pyridine-3-carboxamide (8).
NaNO2 (27 mg, 0.39 mmol) was added to a stirred solution
amide 5 (119 mg, 0.270 mmol) in DCM (5 mL). A balloon
with O2 gas was connected via septum, TFA (352 μL, 4.58
mmol) was added dropwise and the reaction mixture was
stirred at rt for 1 h. The reaction was quenched with sat.
NaHCO3Ĳaq) and extracted with DCM (×3). The combined
organic layers were dried (Na2SO4) and concentrated under
reduced pressure. The product was partially purified by flash
chromatography (SiO2, 20–100% EtOAc in heptane) to afford
the crude intermediate (82 mg). The crude (66 mg) was
dissolved in acetic acid and freshly activated Zn dust (45 mg,
0.69 mmol) was added in portions to control the temperature
of the reaction and stirred at rt for 15 h. Additional activated
Zn dust (24 mg, 0.37 mmol) was added and the reaction
mixture was stirred at rt for 24 h and additional zinc dust (26
mg, 0.40 mmol) was added. After 48 h, the reaction mixture
was filtered through a pad of celite, washing with DCM, and
quenched with sat. NaHCO3Ĳaq). The mixture was extracted
with DCM (×2), the combined organic layers were washed
with NaHCO3 and then brine, dried (Na2SO4) and
concentrated under reduced pressure. Purification by flash
chromatography (SiO2, 30–100% EtOAc in heptane) and
freeze-drying from H2O :MeCN (10 : 1) afforded the amide 8
as a grey powder (30 mg, 30%). 1H-NMR (400 MHz, CDCl3) δ
10.40 (s, br, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.93–7.88 (m, 1H),
7.77 (d, J = 8.3 Hz, 1H), 7.64–7.52 (m, 4H), 7.39–7.28 (m, 3H),
7.17–7.07 (m, 2H), 5.85 (d, J = 7.5 Hz, 1H), 4.38, 4.31 (ABq,
JAB = 16.5 Hz, 2H), 4.20 (d, J = 11.3 Hz, 1H), 3.99 (s br, 2H),
3.68 (dd, J = 7.7, 11.3 Hz, 1H), 3.58 (s, 3H). 13C-NMR (100
MHz, CDCl3) δ 164.7, 156.3, 139.1, 138.1, 134.1, 133.2, 132.1,
131.8, 129.1*, 127.8, 126.6, 126.1, 125.7, 124.7, 124.6, 124.5,
124.1, 123.4, 120.1, 65.5, 61.4, 30.3, 28.2. HRMS (ESI+) (m/z):
[M + H+]+ calcd. for C26H24N3O3S, 458.1532; found, 458.1523.
*Note: overlap of two non-identical aromatic carbons, can be
seen in HSQC.
6-Amino-8-methoxy-7-(naphthalen-1-ylmethyl)-5-oxo-N-
(p-tolyl)-2,3-dihydrothiazoloĳ3,2-a]pyridine-3-carboxamide (9).
NaNO2 (18 mg, 0.26 mmol) was added to a stirred mixture of
amide 6 (78 mg, 0.17 mmol), in DCM (5 mL). A balloon with
O2 gas was connected via septum, TFA (224 μL, 2.92 mmol)
was added dropwise and the reaction mixture was stirred at
rt for 7 h. The reaction was quenched with sat. NaHCO3Ĳaq)
and extracted with DCM (×3). The combined organic layers
were washed with sat. NaHCO3Ĳaq) (×2), dried (Na2SO4) and
concentrated under reduced pressure. The crude (86 mg) was
dissolved in acetic acid (4 mL) and freshly activated Zn dust
(58 mg, 0.89 mmol) was added in portions to control the
temperature of the reaction and the reaction mixture was
stirred at rt for 15 h. Additional Zn dust (56 mg, 0.86 mmol)
were added and stirred for another 7 h. Additional Zn dust
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(28 mg, 0.43 mmol) was added and the reaction mixture was
stirred at rt for another 19 h. The reaction mixture was
filtered through a pad of celite, washed with DCM, and
quenched with sat. NaHCO3Ĳaq). The mixture was extracted
with DCM (×2) and the combined organic layers were washed
with sat. NaHCO3Ĳaq) and then brine, dried (Na2SO4) and
concentrated under reduced pressure. Purification by flash
chromatography (SiO2, 30–100% EtOAc in Heptane) and
freeze-drying from H2O :MeCN afforded the amine 9 as a grey
powder (28 mg, 35%). 1H-NMR (400 MHz, CDCl3) δ 10.29 (br
s, 1H), 8.17 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.77
(d, J = 8.2 Hz, 1H), 7.64–7.52 (m, 2H), 7.50–7.45 (m, 2H),
7.40–7.33 (m, 1H), 7.16–7.08 (m, 3H), 5.84 (d, J = 7.6 Hz, 1H),
4.38, 4.30 (ABq, JAB = 16.5 Hz, 2H), 4.20 (d, J = 11.2 Hz, 1H),
3.98 (br s, 2H), 3.67 (dd, J = 7.6, 11.2 Hz, 1H), 3.58 (s, 3H),
2.31 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ 164.6, 156.3, 139.1,
135.5, 134.0, 133.1, 132.1, 131.8, 129.5, 129.0, 127.8, 126.6,
126.1, 125.7, 124.6, 124.1, 123.4, 120.1, 65.5, 61.4, 30.3, 28.2,
21.0. HRMS (ESI+) (m/z): [M + H+]+ calcd. for C27H26N3O3S,
472.1688; found, 472.1687.
Methyl (R)-7-(2,3-dimethylbenzyl)-8-methoxy-5-oxo-2,3-
dihydrothiazoloĳ3,2-a]pyridine-3-carboxylate (15). TFA (1.925
mL, 25.07 mmol) was added dropwise to a mixture of
2,3-dimethyl Meldrum's acid 14 (18.311 g, 63.074 mmol) and
13 (4.732 g, 25.01 mmol) in DCE (60 mL) and heated in MWI
at 120 °C for 3 min (run in 6 batches). The reaction mixture
was allowed to cool to rt, then diluted with EtOAc and
quenched with sat. NaHCO3Ĳaq). The aqueous layer was
extracted with EtOAc (×3) and the combined organic layers
were washed successively with H2O and brine, dried (Na2SO4),
and concentrated under reduced pressure. Purification by
flash chromatography (SiO2, EtOAc in heptane, 30–100%)
afforded the methyl ester 15 as a yellow-orange powder (7.2
g, 80%). 1H-NMR (400 MHz, CDCl3) δ 7.09–7.01 (m, 2H),
6.98–6.94 (m, 1H), 5.69 (s, 1H), 5.55 (dd, J = 8.3, 2.2 Hz, 1H),
3.90–3.78 (m, 5H), 3.77–3.69 (m, 4H), 3.57 (dd, J = 11.7, 2.2
Hz, 1H), 2.28 (s, 3H), 2.10 (s, 3H). 13C-NMR (100 MHz, CDCl3)
δ 168.4, 160.5, 152.1, 138.2, 137.4, 137.1, 135.3, 129.0, 128.4,
125.8, 114.9, 63.2, 60.7, 53.4, 34.0, 32.5, 20.8, 15.5. Optical
rotation: [α]2D = −32 (c 0.001, CHCl3). HRMS (ESI+) (m/z): [M +
H+]+ calcd. for C19H22NO4S, 360.1264; found, 360.1274.
7-(2,3-Dimethylbenzyl)-8-methoxy-5-oxo-N-phenyl-2,3-
dihydrothiazolo[3,2-a]pyridine-3-carboxamide (16). Methyl
ester 15 (912 mg, 2.54 mmol) was dissolved in THF (50 mL)
and 1 M LiOH(aq) (5 mL) was added and the reaction mixture
was stirred at for 15 h. Diluted the reaction mixture with
EtOAc extracted the with 1 M NaOH(aq) (×3). The combined
aqueous layers were cooled on ice and acidified with 1 M and
conc. HCl until ∼pH 1 and extracted with EtOAc (×4). The
formed precipitate (product) was filtered off from the organic
layer. The organic layer was dried washed with brine and
concentrated under reduced pressure and then freeze dried
the crude (1.299 g). The crude (149 mg) was suspended in
anhydrous MeCN/EtOAc (1 : 1, 4 mL) and after cooling the
suspension to ≃10 °C (NaCl/ice), pyridine (0.11 mL, 1.4
mmol) was added. After stirring for 5 min, aniline (60 μL,
0.66 mmol) was added, followed by dropwise addition of T3P
(50% in EtOAc; 0.52 mL, 1.7 mmol). The reaction mixture
was stirred at −10 °C for 1 h, then allowed to return to rt and
stirred for 23 h. The reaction was cooled to 0 °C, then
quenched with 1 M HCl(aq), diluted with EtOAc and extracted
with EtOAc (×3). The combined organic layers were washed
successively with H2O (1 mL 1 M HCl(aq) was added to aid
separation) and brine, dried (Na2SO4), and concentrated
under reduced pressure. Purification by flash
chromatography (SiO2, 25–100% EtOAc in heptane) and
freeze-drying from H2O :MeCN (6 : 1) afforded the amide 16
as a white powder (101 mg, 82%). 1H-NMR (600 MHz, CDCl3)
δ 10.43 (s, 1H), 7.57–7.53 (m, 2H), 7.30–7.25 (m, 2H), 7.11–
7.04 (m, 3H), 6.95 (d, J = 7.3 Hz, 1H), 5.81 (d, J = 8.0 Hz, 1H),
5.78 (s, 1H), 4.21 (d, J = 11.2 Hz, 1H), 3.90, 3.82 (ABq, JAB =
17.3 Hz, 2H), 3.71 (s, 3H), 3.66 (dd, J = 11.2, 8.0 Hz, 1H), 2.29
(s, 3H), 2.10 (s, 3H). 13C-NMR (151 MHz, CDCl3) δ 164.5,
161.6, 152.9, 140.3, 138.4, 138.0, 137.5, 135.3, 135.0, 129.2,
129.0, 128.4, 125.9, 124.5, 120.0, 114.2, 65.3, 60.7, 33.9, 30.4,
20.8, 15.6. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C24H25N2O3S, 421.1580; found, 421.1589.
7-(2,3-Dimethylbenzyl)-8-methoxy-5-oxo-N-(p-tolyl)-2,3-
dihydrothiazolo[3,2-a]pyridine-3-carboxamide (17). Methyl
ester 15 (912 mg, 2.54 mmol) was dissolved in THF (50 mL)
and 1 M LiOH(aq) (5 mL) was added and the reaction
mixture was stirred at for 15 h. Diluted the reaction mixture
with EtOAc extracted the with 1 M NaOH(aq) (×3). The
combined aqueous layers were cooled on ice and acidified
with 1 M and conc. HCl until ∼pH 1 and extracted with
EtOAc (×4). The formed precipitate (product) was filtered off
from the organic layer. The organic layer was dried, washed
with brine and concentrated under reduced pressure and
freeze dried (1.299 g). A portion (149 mg) was suspended in
anhydrous MeCN/EtOAc (1 : 1, 4 mL) and after cooling the
suspension to ≃10 °C (NaCl/ice), pyridine (0.11 mL, 1.4
mmol) was added. After stirring for 15 min, p-methylaniline
(70 mg, 0.65 mmol) was added and followed by dropwise
addition of T3P (50% in EtOAc; 0.51 mL, 0.86 mmol).
Stirred at −10 °C for 1 h and then allowed to return to rt
and stirred for 23 h. The reaction mixture was cooled to 0
°C and quenched with 1 M HCl(aq), diluted with EtOAc and
extracted with EtOAc (×3). The combined organic layers were
washed successively with water and brine, dried (Na2SO4)
and concentrated under reduced pressure. Purification by
flash chromatography (SiO2, 25–100% EtOAc in heptane)
and freeze-drying from H2O :MeCN afforded the amide 17
as an off-white powder (49 mg, 39%). 1H-NMR (400 MHz,
CDCl3) δ 10.28 (s br, 1H), 7.45–7.40 (m, 2H), 7.12–7.03 (m,
4H), 6.98–6.93 (m, 1H), 5.80–5.73 (m, 2H), 4.21 (d, J = 11.2
Hz, 1H), 3.90, 3.82 (ABq, JAB = 17.3 Hz, 2H), 3.72 (s, 3H),
3.64 (dd, J = 7.9, 11.2 Hz, 1H), 2.31–2.27 (m, 6H), 2.10 (s,
3H). 13C-NMR (100 MHz, CDCl3) δ 164.3, 161.7, 152.6,
140.0, 138.2, 137.5, 135.4, 135.3, 135.0, 134.0, 129.5 (2C),
129.1, 128.4, 125.9, 120.0 (2C), 114.3, 65.1, 60.7, 33.9, 30.3,
20.9, 20.8, 15.6. HRMS (ESI+) (m/z): [M + Na+]+ calcd. for
C25H26N2NaO3S, 457.1555; found, 457.1572.
MedChemCommResearch Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 6
/1
8/
20
20
 4
:0
3:
44
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Med. Chem. Commun., 2019, 10, 1966–1987 | 1979This journal is © The Royal Society of Chemistry 2019
7-(2,3-Dimethylbenzyl)-N-(3-fluoro-5-methylphenyl)-
8-methoxy-5-oxo-2,3-dihydrothiazoloĳ3,2-a]pyridine-3-
carboxamide (18). Methyl ester 15 (4.705 g, 13.09 mmol) was
dissolved in THF (130 mL) and 1 M LiOH(aq) (26 mL) was
added and stirred at rt for 17 h. The reaction mixture was
cooled on ice and quenched with 1 M HCl(aq) (35 mL),
extracted with EtOAc (×4), and combined organic layers were
washed with brine. The formed precipitate (product) was
filtered off from the organic layer. The organic layer was dried
(Na2SO4) and concentrated under reduced pressure to yield
the crude (4.3 g). The crude (3.09 g) was suspended in DCM
(60 mL) and 3-fluoro-5-methylaniline (1.20 mL, 10.7 mmol), N,
N-diisopropyl ethyl amine (3.09 mL, 17.9 mmol) and HATU
(4.25 g, 11.2 mmol) were added and stirred at rt under for 2 h.
The reaction mixture was cooled on ice and 0.5 M HCl(aq) (100
mL) was added in portions. The mixture was diluted with
EtOAc and the aqueous layer was extracted with EtOAc (×2).
The combined organic layers were washed with 0.5 M HCl(aq)
(×2), H2O (×2, added 1 M HCl(aq) to aid separation), and brine
(×4), then dried (Na2SO4) and concentrated under reduced
pressure. Purification by flash chromatography (SiO2, 20–
100% EtOAc in heptane) afforded the product as a yellow
foam (4.02 g, 95%). To obtain the product in crystalline form
the product was recrystallized. The product was combined
with a previous batch and the product (4.935 g) was
recrystallized from boiling EtOH and dried under vacuum,
which afforded the amide 18 as white crystals (3.329 g). 1H
NMR (400 MHz, CDCl3) δ 10.50 (s br, 1H), 7.37–7.31 (m, 1H),
7.12–7.02 (m, 2H), 7.00–6.92 (m, 2H), 6.60 (d, J = 9.2 Hz, 1H),
5.82–5.74 (m, 2H), 4.21 (d, J = 11.2 Hz, 1H), 3.91, 3.82 (ABq,
JAB = 17.3 Hz, 2H), 3.72 (s, 3H), 3.67 (dd, J = 8.0, 11.2 Hz, 1H),
2.30–2.26 (m, 6H), 2.10 (s, 3H). 13C NMR (100 MHz, CDCl3) δ
164.7, 162.9 (d, JCF = 246.3 Hz), 161.7, 152.9, 140.8 (d, JCF = 9.3
Hz), 140.0, 139.0 (d, JCF = 11.7 Hz), 138.4, 137.6, 135.3, 135.0,
129.2, 128.4, 125.9, 116.1 (d, JCF = 2.4 Hz), 114.4, 111.9 (d, JCF
= 21.4 Hz), 104.7 (d, JCF = 26.7 Hz), 65.2, 60.8, 34.0, 30.2, 21.5
(d, JCF = 2.0 Hz), 20.8, 15.6.
19F NMR (376 MHz, CDCl3) δ
−113.00. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C25H26FN2O3S, 453.1642; found, 453.1656.
7-(2,3-Dimethylbenzyl)-8-methoxy-3-(3-phenyl-1,2,4-
oxadiazol-5-yl)-2,3-dihydrothiazolo[3,2-a]pyridin-5-one (19).
Methyl ester 15 (578 mg, 1.61 mmol) was dissolved in THF
and 1 M LiOH(aq) (3.3 mL) was added and stirred at rt for 22
h. 1 M HCl(aq) (5 mL) was added to the reaction mixture and
then extracted with EtOAc (×3). The combined organic layers
were washed with brine and the formed precipitate (product)
was filtered off from the organic layer. The organic layer was
dried (Na2SO4) and concentrated under reduced pressure to
yield the acid (445 mg), which was used without purification.
A portion (188 mg) was suspended in anhydrous DMF (4.3
mL) and benzamidoxime (89 mg, 0.65 mmol), TBTU (209 mg,
0.65 mmol), and diisopropyl ethyl amine (221 μL, 1.28 mmol)
were added and the reaction mixture heated in MWI at 170
°C for 12 min. The reaction mixture was diluted with EtOAc
and 0.5 M HCl(aq) and extracted with EtOAc (×3). The
combined organic layers were washed successively with
KHSO4Ĳaq) (3% w/v) (×2), H2O and brine, dried (Na2SO4) and
concentrated under reduced pressure. Purification by flash
chromatography (SiO2, 30–100% EtOAc in Heptane) and
freeze-drying from H2O :MeCN (6 : 1) afforded the 1,2,4-
oxadiazole 19 as a yellow powder (139 mg, 46%). 1H-NMR
(400 MHz, CDCl3) δ 8.06–8.01 (m, 2H), 7.53–7.43 (m, 3H),
7.11–7.04 (m, 2H), 7.02–6.97 (m, 1H), 6.40 (dd, J = 1.7, 7.8
Hz, 1H), 5.76–5.74 (m, 1H), 3.97 (dd, J = 7.8, 11.8 Hz, 1H),
3.94–3.83 (m, 2H), 3.77–3.71 (m, 4H), 2.30 (s, 3H), 2.13 (s,
3H). 13C-NMR (100 MHz, CDCl3) δ 175.1, 168.9, 160.4, 152.7,
137.6, 137.52, 137.49, 135.3, 135.2, 131.6, 129.2, 129.0, 128.4,
127.8, 126.4, 125.9, 115.4, 60.9, 58.3, 34.2, 34.1, 20.8, 15.6.
HRMS (ESI+) (m/z): [M + H+]+ calcd. for C25H24N3O3S,
446.1532; found, 446.1531.
6-Amino-7-(2,3-dimethylbenzyl)-8-methoxy-3-(3-phenyl-
1,2,4-oxadiazol-5-yl)-2,3-dihydrothiazolo[3,2-a]pyridin-5-one
(20). NaNO2 (18 mg, 0.26 mmol) was added to a stirred
mixture of 1,2,4-oxadiazole 19 (110 mg, 0.247 mmol) in DCM
(5 mL). A balloon with O2 gas was connected via septum, TFA
(323 μL, 4.21 mmol) was added dropwise and the mixture
was stirred at room temperature for 1 h. The reaction was
quenched with sat. NaHCO3Ĳaq) and extracted with DCM (×3).
The combined organic layers were dried (Na2SO4) and
concentrated under reduced pressure. The resulting
intermediate (121 mg) was dissolved in acetic acid (4 mL)
and freshly activated Zn dust (113 mg, 1.73 mmol) was added
in portions to control the temperature of the reaction and it
was stirred at rt for 19 h. The reaction mixture was filtered
through a pad of celite, washed with DCM, and quenched
with sat. NaHCO3Ĳaq). The mixture was extracted with DCM
(×2) and the combined organic layers were washed
successively with sat. NaHCO3Ĳaq) and brine, dried (Na2SO4)
and concentrated under reduced pressure. Purification by
flash chromatography (SiO2, 30–100% EtOAc in heptane) and
freeze-drying from H2O :MeCN (10 : 1) afforded the amine 20
as a grey powder (68 mg, 60%). 1H-NMR (400 MHz, CDCl3) δ
8.09–8.04 (m, 2H), 7.53–7.43 (m, 3H), 7.09–6.98 (m, 2H), 6.86
(d, J = 7.4, 1H), 6.47 (dd, J = 1.8, 7.5 Hz, 1H), 4.07–3.81 (m,
5H), 3.73 (dd, J = 1.8, 11.8 Hz, 1H), 3.59 (s, 3H), 2.33 (s, 3H),
2.30 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ 175.3, 168.8, 155.7,
138.4, 137.3, 135.4, 134.4, 133.2, 131.5, 128.9 (2C), 128.7,
127.7 (2C), 126.4, 125.9, 124.5, 124.0, 122.0, 61.3, 58.6, 34.1,
29.3, 20.8, 15.3. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C25H25N4O3S, 461.1641; found, 461.1639.
6-Amino-7-(2,3-dimethylbenzyl)-8-methoxy-5-oxo-N-phenyl-
2,3-dihydrothiazolo[3,2-a]pyridine-3-carboxamide (21). NaNO2
(19 mg, 0.28 mmol) was added to a stirred mixture of amide
16 (80 mg, 0.19 mmol) in DCM (5 mL). A balloon with O2 gas
was connected via septum, TFA (247 μL, 3.22 mmol) was
added dropwise and the mixture was stirred at room
temperature for 2.5 h. The reaction was quenched with sat.
NaHCO3Ĳaq) and extracted with DCM (×3). The combined
organic layers were dried (Na2SO4) and concentrated under
reduced pressure. The resulting intermediate (67 mg) was
dissolved in acetic acid (4 mL) and freshly activated Zn dust
(66 mg, 1.0 mmol) was added in portions to control the
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temperature of the reaction, and it was stirred at rt for 16 h.
Additional Zn dust (32 mg, 0.49 mmol) was added and stirred
at rt for 4 h. The reaction mixture was filtered through a pad
of celite, washed with DCM, and quenched with sat.
NaHCO3Ĳaq). The mixture was extracted with DCM (×2) and
the combined organic layers were washed successively with
sat. NaHCO3Ĳaq) and brine, dried (Na2SO4) and concentrated
under reduced pressure. Purification by flash
chromatography (SiO2, 30–100% EtOAc in heptane), and
freeze-drying from H2O :MeCN (10 : 1) afforded the amine 21
as a grey powder (25 mg, 30%). 1H-NMR (400 MHz, CDCl3) δ
10.41 (bs, 1H) 7.61–7.55 (m, 2H), 7.34–7.28 (m, 2H), 7.12–
7.04 (m, 2H), 7.03–6.97 (m, 1H), 6.80 (d, J = 7.5 Hz, 1H), 5.85
(d, J = 7.6 Hz, 1H), 4.19 (d, J = 11.2 Hz, 1H), 4.01–3.78 (m,
4H), 3.66 (dd, J = 7.6, 11.2 Hz, 1H), 3.57 (s, 3H), 2.33 (s, 3H),
2.29 (s, 3H). 13C-NMR (100 MHz, CDCl3) δ 164.8, 156.3, 139.1,
138.1, 137.4, 135.4, 134.3, 132.9, 129.0, 128.8, 126.0, 125.6,
124.5, 124.4, 120.1, 65.5, 61.3, 30.3, 29.3, 20.8, 15.3. HRMS
(ESI+) (m/z): [M + H+]+ calcd. for C24H26N3O3S, 436.1689;
found, 436.1691.
6-Amino-7-(2,3-dimethylbenzyl)-8-methoxy-5-oxo-N-(p-
tolyl)-2,3-dihydrothiazolo[3,2-a]pyridine-3-carboxamide (22).
NaNO2 (10 mg, 0.14 mmol) was added to a stirred mixture of
amide 17 (34 mg, 0.078 mmol) in DCM (5 mL). A balloon
with O2 gas was connected via septum, TFA (101 μL, 1.32
mmol) was added dropwise and the mixture was stirred at
room temperature for 4 h. The reaction was quenched with
sat. NaHCO3Ĳaq) and extracted with DCM (×3). The combined
organic layers were washed with sat. NaHCO3Ĳaq) (×2), dried
(Na2SO4) and concentrated under reduced pressure. The
resulting intermediate was dissolved in acetic acid (4 mL)
and freshly activated Zn dust (40 mg, 0.61 mmol) was added
in portions to control the temperature of the reaction and it
was stirred at rt for 15 h. Additional Zn dust (45 mg, 0.69
mmol) were added and after 8 h of additional stirring, the
reaction mixture was filtered through a pad of celite, washed
with DCM, and quenched with sat. NaHCO3Ĳaq). The mixture
was extracted DCM (×2) and the combined organic layers
were washed successively with sat. NaHCO3Ĳaq) and brine,
dried (Na2SO4) and concentrated under reduced pressure.
Purification by flash chromatography (SiO2, 30–100% EtOAc
in heptane) and freeze-drying from H2O :MeCN (10 : 1)
afforded the amine 22 as an off-white powder (5.8 mg, 17%).
1H-NMR (400 MHz, CDCl3) δ 10.29 (br s, 1H), 7.49–7.43 (m,
2H), 7.14–7.08 (m, 2H), 7.08–7.03 (m, 1H), 7.03–6.96 (m, 1H),
6.79 (d, J = 7.5 Hz, 1H), 5.84 (d, J = 7.6 Hz, 1H), 4.20 (d, J =
11.2 Hz, 1H), 4.05–3.77 (m, 4H), 3.66 (dd, J = 7.6, 11.2 Hz,
1H), 3.57 (s, 3H), 2.34–2.27 (9H). 13C-NMR (100 MHz, CDCl3)
δ 164.6, 156.4, 139.1, 137.4, 135.5, 135.4, 134.3, 134.1, 132.9,
129.6, 128.8, 126.0, 125.6, 124.61, 124.57, 120.1, 65.5, 61.3,
30.3, 29.4, 21.0, 20.9, 15.4. HRMS (ESI+) (m/z): [M + H+]+
calcd. for C25H28N3O3S, 450.1845; found, 450.1848.
6 -Amino -7 - ( 2 , 3 -d ime thy lbenz y l ) -N - ( 3 - f l uo ro - 5 -
methylphenyl)-8-methoxy-5-oxo-2,3-dihydrothiazoloĳ3,2-a]-
pyridine-3-carboxamide (23). NaNO2 (13 mg, 0.19 mmol) was
added to a stirred mixture of amide 18 (51 mg, 0.11 mmol) in
DCM (5 mL). A balloon with O2 gas was connected and TFA
(147 μL, 1.92 mmol) was added dropwise and the mixture
was stirred at room temperature for 6 h. The reaction was
quenched with sat. NaHCO3Ĳaq) and extracted with DCM (×3).
The combined organic layers were washed with sat.
NaHCO3Ĳaq) (×2), dried (Na2SO4) and concentrated under
reduced pressure. The crude was dissolved in acetic acid (4
mL) and freshly activated Zn dust (59 mg, 0.90 mmol) was
added in portions to control the temperature of the reaction
and it was stirred at rt for 15 h. Additional Zn dust (23 mg,
0.35 mmol) were added and after 7 h of additional stirring,
the reaction mixture was filtered through a pad of celite,
washed with DCM, and quenched with sat. NaHCO3Ĳaq). The
mixture was extracted DCM (×2) and the combined organic
layers were washed successively with sat. NaHCO3Ĳaq) and
brine, dried (Na2SO4) and concentrated under reduced
pressure. Purification by flash chromatography (SiO2, 30–
100% EtOAc in heptane) and freeze-drying from H2O :MeCN
(10 : 1) afforded the amine 23 as a brown powder (20 mg,
39%). 1H-NMR (400 MHz, CDCl3) δ 10.48 (br s, 1H), 7.36–7.30
(m, 1H), 7.08–6.96 (m, 3H), 6.81–6.77 (m, 1H), 6.65–6.58 (m,
1H), 5.82 (d, J = 7.7 Hz, 1H), 4.17 (d, J = 11.3 Hz, 1H), 4.02–
3.77 (m, 4H), 3.66 (dd, J = 7.7, 11.3 Hz, 1H), 3.57 (s, 3H), 2.32
(s, 3H), 2.31–2.28 (m, 6H). 13C-NMR (100 MHz, CDCl3) δ
164.9, 163.0 (d, JCF = 244.1 Hz), 156.4, 140.8 (d, JCF = 8.9 Hz),
139.3, 139.1 (d, JCF = 11.5 Hz), 137.5, 135.4, 134.2, 132.9,
128.8, 126.0, 125.8, 124.6, 124.5, 116.1 (d, JCF = 2.6 Hz), 111.9
(d, JCF = 21.2 Hz), 104.7 (d, JCF = 26.5 Hz), 65.5, 61.3, 30.2,
29.4, 21.5 (d, JCF = 2.0 Hz), 20.9, 15.4.
19F NMR (376 MHz,
CDCl3) δ −113.29. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C25H27FN3O3S, 468.1751; found, 468.1751.
tert-Butyl (8-methoxy-7-(naphthalen-1-ylmethyl)-5-oxo-3,5-
dihydro-2H-thiazoloĳ3,2-a]pyridin-3-yl)carbamate (10).
Carboxylic acid 4 (500 mg, 1.36 mmol) was suspended in
t-BuOH (10 ml). DPPA (308 μl, 1.43 mmol) and TEA (199 μl,
1.43 mmol) were added and the mixture was heated to 85 °C
for 2 hours. Filtered and concentrated. The residue was
purified using column chromatography on silica gel
(heptane : EtOAc 83 : 17 ≥ 0 : 100) to give BOC-protected
amine 10 as a yellow foam (358 mg, 60%). 1H-NMR (400
MHz, CDCl3) δ 7.87–7.78 (m, 2H), 7.77 (d, J = 7.9 Hz, 1H),
7.48–7.43 (m, 2H), 7.40 (dd, J = 8.4, 6.9 Hz, 1H), 7.30 (dd, J =
6.9, 0.9 Hz, 1H), 6.47 (td, J = 6.8, 0.9 Hz, 1H), 5.67 (s, 1H),
5.56 (d, J = 7.2 Hz, 1H), 4.23 (s, 2H), 3.71 (s, 3H), 3.63 (dd, J =
11.9, 6.5 Hz, 1H), 3.39 (dd, J = 11.9, 1.7 Hz, 1H), 1.42 (s, 9H);
13C-NMR (100 MHz, CDCl3) δ 159.6, 154.1, 151.6, 138.3,
136.4, 134.0, 133.4, 131.8, 128.8, 127.9, 127.8, 126.4, 125.8,
125.5, 123.8, 115.6, 80.8, 69.1, 60.7, 36.0, 32.7, 28.3; HRMS
(ESI+) (m/z): [M + H+]+ calcd. for C24H27N2O4S
+, 439.1686;
found, 439.1691.
3-Amino-8-methoxy-7-(naphthalen-1-ylmethyl)-2H-thiazolo-
ĳ3,2-a]pyridin-5Ĳ3H)-one (11). BOC-protected amine 10 (345
mg, 0.787 mmol) was dissolved in a mixture of DCM (9 ml)
and TFA (3 ml) and stirred at room temperature for 2 hours.
Quenched with NaHCO3 (sat. aq) and extracted with EtOAc.
Dried (Na2SO4), filtered and concentrated. Purified using
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column chromatography on silica gel (EtOAc :MeOH 99 : 1 ≥
92 : 8) to give amine 11 as a yellow foam (85 mg, 32%). 1H-
NMR (400 MHz, CDCl3) δ 7.89–7.80 (m, 2H), 7.78 (d, J = 8.0
Hz, 1H), 7.51–7.43 (m, 2H), 7.41 (t, J = 7.8 Hz, 1H), 7.32 (d, J
= 6.8 Hz, 1H), 5.88 (dd, J = 7.3, 1.7 Hz, 1H), 5.69 (s, 1H), 4.26
(s, 2H), 3.73 (s, 3H), 3.66 (dd, J = 12.0, 7.1 Hz, 1H), 3.16 (dd,
J = 12.0, 1.6 Hz, 1H), 2.48 (s, 2H); 13C-NMR (100 MHz, CDCl3)
δ 160.6, 151.3, 137.3, 136.4, 134.0, 133.5, 131.9, 128.9, 127.9,
127.9, 126.4, 125.8, 125.5, 123.9, 115.3, 72.9, 60.8, 35.7, 32.7;
HRMS (ESI+) (m/z): [M + H+]+ calcd. for C19H19N2O2S
+,
339.1162; found, 339.1167.
8-Methoxy-7-(naphthalen-1-ylmethyl)-3-(4-phenyl-1H-1,2,3-
triazol-1-yl)-2H-thiazolo[3,2-a]pyridin-5(3H)-one (12). Amine
11 (60 mg, 0.18 mmol) was dissolved in dry MeOH (1 ml) and
K2CO3 (54 mg, 0.39 mmol) followed by CuSO4 (5.7 mg, 0.036
mmol) were added. Imidazole-1-sulfonyl azide·H2SO4 (101 mg,
0.372 mmol) was added and the reaction was heated to 50 °C
for 40 h. Diluted with EtOAc and washed with brine. The
water layers were extracted with EtOAc and the organic layers
were dried (Na2SO4), filtered and concentrated. The product
was partially purified by column chromatography (SiO2,
heptane : EtOAc 90 : 10 ≥ 20 : 80, Rf = 0.3), then dissolved in
DMF (0.5 ml) and phenyl acetylene (4.2 μl, 0.038 mmol),
sodium ascorbate (1.5 mg, 0.0077 mmol), CuSO4 (0.61 mg,
0.0038 mmol) and H2O (50 μl) were added. The mixture was
stirred for 4 hours and then diluted with EtOAc and washed
with brine. The organic layer was dried (Na2SO4), filtered and
concentrated under reduced pressure. Purified using
preparative HPLC (H2O :MeCN 90 : 10 ≥ 0 : 100 with 0.75%
formic acid over 40 minutes) to give 1,2,3-triazole 12 as a
yellow solid (4 mg, 45%). 1H-NMR (400 MHz, CDCl3) δ 8.20
(s, 1H), 7.89–7.84 (m, 1H), 7.82–7.77 (m, 4H), 7.49–7.45 (m,
2H), 7.44–7.37 (m, 3H), 7.35–7.28 (m, 3H), 5.68 (t, J = 1.1 Hz,
1H), 4.35 (d, J = 12.7 Hz, 1H), 4.33, 4.22 (ABq, JAB = 17.2 Hz,
2H), 4.05 (dd, J = 12.5, 7.1 Hz, 1H), 3.79 (s, 3H); 13C-NMR
(100 MHz, CDCl3) δ 160.0, 153.4, 148.1, 138.6, 137.2, 134.1,
133.0, 131.9, 130.2, 129.1, 129.0, 128.9, 128.5, 128.2, 128.1,
126.6, 126.0, 125.7, 123.9, 121.0, 115.4, 73.0, 61.0, 33.9, 33.0;
HRMS (ESI+) (m/z): [M + H+]+ calcd. for C27H23N4O2S
+,
467.1536; found, 467.1540.
8-cyclopropyl-7-(naphthalen-1-ylmethyl)-5-oxo-N-phenyl-
3,5-dihydro-2H-thiazoloĳ3,2-a]pyridine-3-carboxamide.
Prepared according to previously published procedures in
ref. 10.
8-(Isopropylamino)-7-(naphthalen-1-ylmethyl)-5-oxo-N-
phenyl-2,3-dihydrothiazolo[3,2-a]pyridine-3-carboxamide (26).
Ammonium salt 25 (70 mg, 0.16 mmol) was combined with
NaBHĲOAc)3 (100 mg, 0.47 mmol) and TFA (60 μL, 0.78
mmol) at −15 °C, then DCM (500 μL) added, followed by
acetone (13.8 μL, 0.19 mmol). The mixture was stirred and
allowed to warm to rt overnight. Additional acetone (1 μL,
0.01 mmol) and NaBHĲOAc)3 (11 mg, 0.05 mmol) were added
and the mixture stirred for another 2 h. The mixture was
then acidified with 1 M HCl(aq) and extracted with EtOAc (×2),
which was then washed with NaHCO3Ĳaq). The combined
organics were dried (MgSO4) and filtered, then the solvent
removed under reduced pressure. The residue was re-
dissolved in THF (1.48 mL) and MeOH (371 μL), then 1 M
LiOH(aq) (800 μL, 0.80 mmol) added and the mixture stirred
at rt for 1 h. Partitioned (EtOAc/1 M HCl(aq)) and the aqueous
re-extracted (×2). The combined organics were dried over
MgSO4, filtered and the solvent removed under reduced
pressure. The residue was re-dissolved in DCM and a large
excess of Eth. HCl(g) added. The mixture was allowed to stand
overnight at −20 °C, then most of the Et2O removed by
pipette, and the residue triturated with fresh Et2O. The
material was dried under vacuum, then dissolved in DMF
(500 μL) and HATU (51 mg, 0.13 mmol), aniline (19 μL, 0.21
mmol) and DIPEA (36 μL, 0.21 mmol 2.08) added. After
stirring for 1 h at rt, the mixture was partitioned (EtOAc/dil.
HCl(aq)) and the aqueous re-extracted (×2), dried (MgSO4),
filtered and the solvent removed under reduced pressure.
Purified by HPLC as described in the general procedure and
freeze-dried from H2O :MeCN to give isopropyl amine 26 as a
white solid (32 mg, 43%). 1H NMR (600 MHz, DMSO-d6) δ
10.36 (s, 1H), 7.99–7.93 (m, 1H), 7.90–7.82 (m, 2H), 7.56–7.48
(m, 5H), 7.43 (d, J = 7.0 Hz, 1H), 7.30 (apparent t, J = 7.7 Hz,
2H), 7.05 (apparent t, J = 7.4 Hz, 1H), 5.48 (d, J = 8.9 Hz, 1H),
5.16 (s, 1H), 4.41, 4.29 (ABq, JAB = 17.1 Hz, 2H), 3.87 (dd, J =
11.9, 9.1 Hz, 1H), 3.62 (br d, J = 6.1 Hz, 1H), 3.50 (d, J = 12.0
Hz, 1H), 3.32–3.25 (m, 1H), 1.13 (d, J = 6.2 Hz, 3H), 1.11 (d, J
= 6.2 Hz, 3H). 13C NMR (151 MHz, DMSO) δ 166.0, 159.3,
154.5, 146.0, 138.7, 134.7, 133.5, 131.5, 128.8, 128.6, 127.9,
127.3, 126.2, 125.8, 125.7, 124.2, 123.5, 120.8, 119.0, 112.8,
64.7, 48.9, 33.4, 31.5, 23.45, 23.42. HRMS (ESI+) (m/z): [M +
H+]+ calcd. for C28H28N3O2S, 470.1897; found, 470.1895.
8-(Dimethylamino)-7-(naphthalen-1-ylmethyl)-5-oxo-N-
phenyl-2,3-dihydrothiazolo[3,2-a]pyridine-3-carboxamide (27).
Ammonium salt 25 (70 mg, 0.16 mmol) was dissolved with
stirring in DMF (500 μL) and NaHCO3 (92 mg, 1.10 mmol)
was added, followed by iodomethane (49 μL, 0.78 mmol). The
resulting mixture was heated to 70 °C and stirred for 10 h.
The mixture was then partitioned (EtOAc/brine) and the
aqueous re-extracted (×2). The combined organics were dried
(MgSO4). The solvent was then removed and replaced with a
mixture of THF (640 μL) and MeOH (140 μL), then 1 M
LiOH(aq) (786 μL, 0.79 mmol) added. The mixture was stirred
at rt and monitored by LC-MS. On completion, the mixture
was partitioned (EtOAc/brine) and the aqueous re-extracted
(×2), then the combined organics dried (MgSO4), filtered and
the solvent removed under reduced pressure. The residue
was re-dissolved in DMF (500 μL) and HATU (59 mg, 0.15
mmol), aniline (23.5 μL, 0.26 mmol) and DIPEA (45 μL 0.26
mmol) added. After stirring for 1 h at rt, the mixture was
partitioned (EtOAc/dil. HCl(aq)) and the aqueous re-extracted
(×2), then the combined organics dried (MgSO4), filtered and
the solvent removed under reduced pressure. Purified by
HPLC as described in the general procedure and freeze-dried
from H2O :MeCN to give dimethylamine 27 as a white solid
(39 mg, 55%). 1H NMR (600 MHz, DMSO-d6) δ 10.39 (s, 1H),
7.96 (d, J = 7.7 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.86 (d, J =
8.2 Hz, 1H), 7.59–7.45 (m, 5H), 7.40 (d, J = 7.0 Hz, 1H), 7.30
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(apparent t, J = 7.8 Hz, 2H), 7.06 (apparent t, J = 7.4 Hz, 1H),
5.45 (d, J = 9.1 Hz, 1H), 5.31 (s, 1H), 4.35, 4.30 (ABq, JAB =
16.7 Hz, 2H), 3.92 (dd, J = 12.0, 9.2 Hz, 1H), 3.55 (d, J = 11.9
Hz, 1H), 2.71 (s, 6H). 13C NMR (151 MHz, DMSO) δ 166.0,
159.5, 156.1, 147.3, 138.7, 134.8, 133.5, 131.5, 128.8, 128.6,
127.6, 127.2, 126.3, 125.8, 125.6, 125.1, 124.0, 123.6, 119.0,
113.0, 63.8, 42.6, 41.8, 33.8, 31.9. HRMS (ESI+) (m/z): [M +
Na+]+ calcd. for C27H25N3O2SNa
+, 478.1565; found, 478.1557.
Me t h y l Ĳ 7 - [ n a p h t h a l e n - 1 - y l m e t h y l ] - 5 - o x o - 3 -
[phenylcarbamoyl]-2,3-dihydrothiazoloĳ3,2-a]pyridin-8-yl)-
carbamate (28). Ammonium salt 25 (70 mg, 0.16 mmol) was
dissolved with stirring in DCM (500 μL) and pyridine (51 μL,
0.63 mmol) was added, followed by methyl chloroformate (30
μL, 0.39 mmol). The resulting mixture was stirred for 2 h,
then partitioned (EtOAc/1 M HCl(aq)) and the aqueous re-
extracted (×2), dried (MgSO4), filtered and the solvent
removed under reduced pressure. The residue was purified
by chromatography (SiO2, DCM/MeOH with 1% Et3N), then
the resulting material dissolved in THF MeOH (200 μL) and 1
M LiOH(aq) (784 μL, 0.784 mmol) were added and the reaction
monitored by TLC until conversion was complete. The
mixture was acidified with 1 M HCl(aq) and extracted with
DCM, then partially purified by chromatography (SiO2,
EtOAc/heptane). The resulting material was dissolved in THF
(1.15 mL) and MeOH (287 μL) then 1 M LiOH(aq) (789 μL,
0.79 mmol) added. After stirring overnight the material had
precipitated, and was triturated with additional THF then
collected. The residue was re-dissolved in DMF (500 μL) and
HATU (53 mg, 0.14 mmol), aniline (19.6 μL, 0.21 mmol) and
DIPEA (37 μL, 0.21 mmol) added. After stirring for 1 h at rt,
the mixture was partitioned (EtOAc/dil. HCl(aq)) and the
aqueous re-extracted (×2), dried (MgSO4), filtered and the
solvent removed under reduced pressure. Purified by HPLC
as described in the general procedure and freeze-dried from
H2O :MeCN to give carbamate 28 as a white solid (29 mg,
38%). 1H NMR (600 MHz, DMSO-d6) δ 10.40 (s, 1H), 8.89* (s,
0.8H), 8.62* (s, 0.2H), 8.01–7.93 (m, 1H), 7.89 (d, J = 8.2 Hz,
1H), 7.87–7.80 (m, 1H), 7.59–7.47 (m, 5H), 7.41 (d, J = 7.0 Hz,
1H), 7.30 (apparent t, J = 7.7 Hz, 2H), 7.06 (t, J = 7.4 Hz, 1H),
5.52 (dd, J = 9.1, 1.6 Hz, 1H), 5.22* (s, 0.2H), 5.15* (s, 0.8H),
4.17, 4.12 (ABq, JAB = 17.1 Hz, 2H), 3.96 (apparent t, J = 10.6
Hz, 1H), 3.65 (s, 3H), 3.56 (d, J = 11.9 Hz, 1H). 13C NMR (151
MHz, DMSO) δ 165.7, 159.6, 155.7, 154.8, 149.8, 138.6, 133.5,
131.5, 128.8, 128.6, 128.1, 127.5, 126.3, 125.8, 125.7, 124.1,
123.6, 119.0, 112.4, 110.9, 65.0, 52.1, 33.6, 31.9. HRMS (ESI+)
(m/z): [M + Na+]+ calcd. for C27H23N3O4SNa
+, 508.1301; found,
508.1298.*Note: rotameric signals.
8-Acetamido-7-(naphthalen-1-ylmethyl)-5-oxo-N-phenyl-2,3-
dihydrothiazolo[3,2-a]pyridine-3-carboxamide (29).
Ammonium salt 25 (70 mg, 0.16 mmol) was dissolved with
stirring in DCM (500 μL) and pyridine (51 μL, 0.63 mmol) was
added, followed by acetyl chloride (28 μL, 0.39 mmol). The
resulting mixture was stirred overnight. MeOH (200 μL) and 1
M LiOH(aq) (784 μL, 0.784 mmol) were added and the reaction
monitored by TLC until conversion was complete. The mixture
was acidified with 1 M HCl(aq) and extracted with DCM, then
partially purified by chromatography (SiO2, EtOAc/heptane).
The resulting material was dissolved in THF (1.42 mL) and
MeOH (355 μL) then 1 M LiOH(aq) (783 μL, 0.78 mmol) added.
After 2 h the material had precipitated, and was triturated with
additional THF then collected. The residue was re-dissolved in
DMF (500 μL) and HATU (61 mg, 0.16 mmol), aniline (22.7 μL,
0.25 mmol) and DIPEA (43 μL, 0.25 mmol) added. After stirring
for 1 h at rt, the mixture was partitioned (EtOAc/dil. HCl(aq))
and the aqueous re-extracted (×2), dried (MgSO4), filtered and
the solvent removed under reduced pressure. Purified by HPLC
as described in the general procedure and freeze-dried from
H2O :MeCN to give amide 29 as a white solid (37 mg, 50%).
1H
NMR (600 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.41 (s, 1H), 7.98–
7.94 (m, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.87–7.83 (m, 1H), 7.59–
7.45 (m, 5H), 7.41 (d, J = 7.0 Hz, 1H), 7.30 (apparent t, J = 7.7
Hz, 2H), 7.06 (apparent t, J = 7.4 Hz, 1H), 5.50 (d, J = 9.1 Hz,
1H), 5.14 (s, 1H), 4.14, 4.08 (ABq, JAB = 17.3 Hz, 2H), 3.94 (dd, J
= 12.0, 9.1 Hz, 1H), 3.56 (d, J = 12.0 Hz, 1H), 2.02 (s, 3H). 13C
NMR (151 MHz, DMSO) δ 169.5, 165.8, 159.6, 154.5, 148.7,
138.6, 133.6, 133.5, 131.5, 128.8, 128.6, 128.1, 127.5, 126.3,
125.8, 125.7, 124.2, 123.6, 119.0, 112.3, 111.3, 64.9, 33.8, 31.8,
22.4. HRMS (ESI+) (m/z): [M + H+]+ calcd. for C27H24N3O3S
+,
470.1533; found, 470.1536.
8-(Methylsulfonamido)-7-(naphthalen-1-ylmethyl)-5-oxo-N-
phenyl-2,3-dihydrothiazolo[3,2-a]pyridine-3-carboxamide (30).
Ammonium salt 25 (70 mg, 0.16 mmol) was dissolved with
stirring in THF (500 μL) and pyridine (50 μL, 0.63 mmol) was
added, followed by methanesulfonyl chloride (30 μL, 0.39
mmol). The resulting mixture was stirred overnight. MeOH
(200 μL) and 1 M LiOH(aq) (784 μL, 0.784 mmol) were added
and the reaction monitored by TLC until conversion was
complete. The mixture was acidified with 1 M HCl(aq) and
partitioned with IPA/brine. The aqueous was re-extracted
(×2), and the combined organics were dried (MgSO4), filtered
and the solvent removed under reduced pressure. The
residue was re-dissolved in DMF (500 μL) and HATU (99 mg,
0.18 mmol), aniline (25.4 μL, 0.28 mmol) and DIPEA (48 μL,
0.28 mmol) added. After stirring for 1 h at rt, the mixture was
partitioned (EtOAc/dil. HCl(aq)) and the aqueous re-extracted
(×2), dried (MgSO4), filtered and the solvent removed under
reduced pressure. Purified by HPLC as described in the
general procedure and freeze-dried from H2O :MeCN to give
methyl sulfonamide 30 as a white solid (41 mg, 52%). 1H
NMR (600 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.31 (s, 1H), 7.97
(d, J = 7.8 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.87 (d, J = 8.1 Hz,
1H), 7.58–7.47 (m, 5H), 7.43 (d, J = 7.0 Hz, 1H), 7.30
(apparent t, J = 7.8 Hz, 2H), 7.06 (apparent t, J = 7.4 Hz, 1H),
5.50 (d, J = 9.0 Hz, 1H), 5.04 (s, 1H), 4.47, 4.31 (ABq, JAB =
17.7 Hz, 2H), 4.04–3.99 (m, 1H), 3.60 (d, J = 11.9 Hz, 1H),
3.22 (s, 3H). 13C NMR (151 MHz, DMSO) δ 165.6, 159.4,
156.3, 151.6, 138.6, 133.8, 133.5, 131.5, 128.8, 128.6, 128.3,
127.6, 126.3, 125.9, 125.7, 124.2, 123.6, 119.0, 112.7, 109.9,
65.0, 43.3, 34.4, 32.1. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C26H24N3O4S2
+, 506.1203; found, 506.1200.
N-(3-Fluoro-5-methylphenyl)-8-(methylsulfonamido)-7-
(naphthalen-1-ylmethyl)-5-oxo-2,3-dihydrothiazoloĳ3,2-a]-
MedChemCommResearch Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 6
/1
8/
20
20
 4
:0
3:
44
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Med. Chem. Commun., 2019, 10, 1966–1987 | 1983This journal is © The Royal Society of Chemistry 2019
pyridine-3-carboxamide (32). Carboxylic acid 31 (70 mg, 0.16
mmol) was dissolved in anhydrous DMF (2.5 mL) and
3-fluoro-5-methylaniline (36 μL, 0.32 mmol), HATU (74 mg,
0.19 mmol) and diisopropyl ethyl amine (57 μL, 0.33 mmol)
were added and stirred at rt for 4 h. The reaction mixture
was cooled on ice and quenched by addition of 0.5 M HCl(aq)
(4 mL) in portions, diluted with EtOAc and the aqueous layer
was extracted with EtOAc (×2). The combined organic layers
were washed successively with 0.5 M HCl(aq) and brine, dried
(Na2SO4) and concentrated under reduced pressure.
Purification by flash chromatography (SiO2, 40–100% EtOAc
in heptane) and freeze-drying from H2O :MeCN (5 : 1)
afforded the amide 32 as an orange powder (43 mg, 49%).
1H-NMR (600 MHz, DMSO-d6) δ 10.55 (s, 1H), 9.32 (s, 1H),
7.98–7.95 (m, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.88–7.85 (m, 1H),
7.54–7.49 (m, 3H), 7.43 (d, J = 6.9 Hz, 1H), 7.30–7.26 (m, 1H),
7.10 (s, 1H), 6.76–6.72 (m, 1H), 5.48 (dd, J = 9.3, 2.0 Hz, 1H),
5.04 (s, 1H), 4.46, 4.32 (ABq, JAB = 17.7 Hz, 2H), 4.01 (dd, J =
11.9, 9.3 Hz, 1H), 3.59 (dd, J = 11.9, 2.0 Hz, 1H), 3.21 (s, 3H),
2.27 (s, 3H). 13C-NMR (151 MHz, DMSO-d6) δ 165.9, 162.0 (d,
JCF = 141.0 Hz), 159.4, 156.3, 151.6, 140.6 (d, JCF = 9.6 Hz),
139.8 (d, JCF = 12.1 Hz), 133.8, 133.5, 131.5, 128.6, 128.3,
127.6, 126.3, 125.9, 125.7, 124.2, 115.4 (CF broad peak), 112.7,
110.8 (d, JCF = 21.2 Hz), 109.9, 103.2 (d, JCF = 26.4 Hz), 65.0,
43.3, 34.4, 21.0 (d, JCF = 2.0 Hz). HRMS (ESI
+) (m/z): [M + H+]+
calcd. for C27H25FN3O4S2, 538.1265; found, 538.1273.
8-(Methylsulfonamido)-7-(naphthalen-1-ylmethyl)-5-oxo-N-
(m-tolyl)-2,3-dihydrothiazoloĳ3,2-a]pyridine-3-carboxamide
(33). Carboxylic acid 31 (70 mg, 0.16 mmol) was dissolved in
anhydrous DMF (2.5 mL) and 3-methylaniline (34 μL, 0.32
mmol), HATU (74 mg, 0.19 mmol), and diisopropyl ethyl
amine (57 μL, 0.33 mmol) were added and stirred under an
inert atmosphere at rt for 4 h. The reaction mixture was
cooled on ice and quenched by addition of 0.5 M HCl(aq) (4
mL) in portions, diluted with EtOAC and aqueous layer was
extracted with EtOAc (×2). The combined organic layers were
washed successively with 0.5 M HCl(aq) and brine (2 mL 0.5
M HCl(aq) was added to aid separation), dried (Na2SO4) and
concentrated under reduced pressure. Purification by flash
chromatography (SiO2, EtOAc in heptane, 70–100%) and
freeze-drying from H2O :MeCN (5 : 1) afforded the amide 33
as beige powder (66 mg, 78%). 1H-NMR (600 MHz, DMSO-d6)
δ 10.32 (s, 1H), 9.32 (s, 1H), 7.99–7.95 (m, 1H), 7.92–7.85 (m,
2H), 7.55–7.49 (m, 3H), 7.44–7.42 (m, 1H), 7.41–7.39 (m, 1H),
7.31–7.27 (m, 1H), 7.18 (t, J = 7.8 Hz, 1H), 6.90–6.86 (m, 1H),
5.49 (dd, J = 9.2, 2.0 Hz, 1H), 5.04 (s, 1H), 4.46, 4.32 (ABq, JAB
= 17.7 Hz, 2H), 4.01 (dd, J = 11.8, 9.2 Hz, 1H), 3.58 (dd, J =
11.8, 2.0 Hz, 1H), 3.21 (s, 3H), 2.25 (s, 3H). 13C-NMR (151
MHz, DMSO-d6) δ 165.6, 159.5, 156.2, 151.6, 138.5, 138.1,
133.9, 133.5, 131.5, 128.7, 128.6, 128.3, 127.6, 126.3, 125.9,
125.7, 124.33, 124.25, 119.6, 116.2, 112.7, 109.9, 65.0, 43.3,
34.4, 32.1, 21.1. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C27H26N3O4S2, 520.1359; found, 520.1362.
Methyl 8-(((benzyloxy)carbonyl)amino)-7-(naphthalen-1-
ylmethyl)-5-oxo-3,5-dihydro-2H-thiazoloĳ3,2-a]pyridine-3-
carboxylate (36). Thiazoline 34 (5.86 g, 19.0 mmol) and acyl
meldrum's acid derivative 35 (19.6 g, 62.7 mmol) were
dissolved in DCM (73 ml) and TFA (1.61 ml, 20.9 mmol) was
added. The solution was split into 7 vials which were then
capped and heated to 70 °C for 20 h. Quenched with NaHCO3
(sat. aq). The water layer was extracted with EtOAc and the
organic layers were dried (Na2SO4), filtered and concentrated.
Purified using column chromatography on silica gel
(heptane : EtOAc 60 : 40 ≥ 0 : 100) to give methyl ester 36 as a
yellow foam (8.12 g, 85%). 1H-NMR (400 MHz, CDCl3) δ 7.90–
7.73 (m, 3H), 7.52–7.41 (m, 2H), 7.41–7.28 (m, 6H), 7.24–7.18
(m, 1H), 5.93 (s, 1H), 5.80–5.65 (m, 1H), 5.54 (dd, J = 8.4, 2.4
Hz, 1H), 5.20–5.10 (m, 2H), 4.27–4.05 (m, 2H), 3.76 (s, 3H),
3.73–3.63 (m, 1H), 3.55–3.45 (m, 1H); 13C-NMR (100 MHz,
CDCl3) δ 168.3, 161.0, 154.9, 154.8, 148.4, 135.9, 134.1, 132.9,
132.0, 128.9, 128.7, 128.5, 128.3, 128.1, 127.7, 126.5, 126.0,
125.6, 124.0, 115.5, 111.5, 67.8, 64.0, 53.5, 34.9, 32.2; HRMS
(ESI+) (m/z): [M + H+]+ calcd. for C28H25N2O5S
+, 501.1479;
found, 501.1476.
BenzylĲ7-(naphthalen-1-ylmethyl)-5-oxo-3-(3-phenyl-1H-
1,2,4-triazol-5-yl)-3,5-dihydro-2H-thiazoloĳ3,2-a]pyridin-8-yl)-
carbamate (37). Methyl ester 36 (300 mg, 0.600 mmol) was
dissolved in THF (2.2 ml) and 1 M LiOH(aq) (1.2 ml) was
added. Stirred at room temperature for 2 h. Diluted with
EtOAc and washed with 1 M HCl. The organic layer was dried
(Na2SO4), filtered and concentrated. The residue was
dissolved in dry DMF (3.6 ml) and benzamidine
hydrochloride hydrate (154 mg, 0.88 mmol), DIPEA (305 μl,
1.76 mmol) and HATU (257 mg, 0.676 mmol) were added.
Stirred at room temperature for 3.5 h (4-methoxybenzyl)-
hydrazine hydrochloride (166 mg, 0.882 mmol) and AcOH
(337 μl, 5.88 mmol) were added and the mixture was heated
to 80 °C for 20 h. Cooled to room temperature and quenched
with NaHCO3 (aq). Extracted with EtOAc. The organic layers
were washed with NaHCO3 (sat. aq), 5% LiCl, water, and
brine and then dried (Na2SO4), filtered, and concentrated.
The residue was suspended in DCM (3.6 ml) and TFA (3.6
ml) was added. Heated to 50 °C for 22 h. Concentrated,
dissolved in EtOAc and washed with NaHCO3 (sat. aq). The
water layer was extracted with EtOAc and the organic layers
were then washed with water and brine. Dried (Na2SO4),
filtered and concentrated. Purified using column
chromatography on silica gel (heptane : EtOAc 25 : 75 ≥ 0 :
100) followed by preperative HPLC (H2O :MeCN 90 : 10 ≥ 0 :
100 with 0.75% formic acid over 40 minutes) to give 1,2,4-
triazole 37 as a yellow solid (135 mg, 39%). 1H-NMR (400
MHz, CDCl3) δ 7.87–7.85 (m, 4H), 7.72 (d, J = 8.4 Hz, 1H),
7.46–7.36 (m, 2H), 7.35–7.21 (m, 9H), 7.11 (d, J = 7.1 Hz, 1H),
6.48 (s, 1H), 6.20 (d, J = 7.3 Hz, 1H), 5.68 (s, 1H), 5.13 (s, 2H),
4.17, 3.95 (ABq, JAB = 17.6 Hz, 2H), 3.78–3.66 (m, 2H);
13C-
NMR (100 MHz, CDCl3) δ 161.7, 158.3, 157.6, 155.7, 155.1,
157.7, 136.0, 134.0, 132.9, 131.9, 130.0, 128.8, 128.8, 128.7,
128.7, 128.4, 128.2, 128.0, 127.8, 126.6, 126.5, 125.9, 125.6,
124.1, 115.0, 112.4, 67.7, 60.8, 34.7, 33.7; LRMS (m/z): [M +
H+]+ calcd. for C34H28N5O3S, 586.2
+; found, 586.3.
N-(7-(Naphthalen-1-ylmethyl)-5-oxo-3-(3-phenyl-1H-1,2,4-
triazol-5-yl)-3,5-dihydro-2H-thiazoloĳ3,2-a]pyridin-8-yl)-
MedChemComm Research Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 6
/1
8/
20
20
 4
:0
3:
44
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1984 | Med. Chem. Commun., 2019, 10, 1966–1987 This journal is © The Royal Society of Chemistry 2019
methanesulfonamide (38). 1,2,4-Triazole 37 (135 mg, 0.231
mmol) was dissolved in DCM (5 ml) and 33% HBr in AcOH
(5 ml) was added. Stirred at room temperature for 2 h. Et2O
was added to precipitate the product (127 mg), which was
collected by filtration and washed with cold Et2O. 15 mg of
this residue was dissolved in pyridine (0.5 ml) and MsCl (6.6
μl, 0.085 mmol) was added. Stirred at room temperature for
18 h. Concentrated and redissolved in a mixture of THF (1
ml) and MeOH (0.4 ml). LiOH (aq) (0.28 ml, 1 M in H2O) was
added and the mixture was stirred at room temperature until
completion (indicated by TLC). Diluted with EtOAc and
washed with water. Dried (Na2SO4), filtered and concentrated.
Purified using preperative HPLC (H2O :MeCN 90 : 10 ≥ 0 : 100
with 0.75% formic acid over 40 minutes) to give methyl
sulfonamide 38 as a yellow powder (8 mg, 53%). 1H-NMR
(400 MHz, DMSO-d6) δ 14.27 (br s, 1H), 9.34 (br s, 1H), 8.01–
7.95 (m, 1H), 7.94–7.86 (m, 4H), 7.57–7.42 (m, 7H), 6.17 (dd,
J = 8.0, 1.1 Hz, 1H), 5.09 (s, 1H), 4.48, 4.34 (ABq, JAB = 17.2
Hz, 2H), 4.10 (dd, J = 11.5, 8.2 Hz, 1H), 3.55 (dd, J = 11.5, 1.1
Hz, 1H), 3.22 (s, 3H); 13C-NMR (150 MHz, DMSO-d6) δ 161.6,
158.4, 157.5, 150.6, 134.1, 133.0, 132.0, 130.2, 128.9 (2C),
128.8, 128.1, 128.1, 126.6, 126.6, 126.0, 125.6, 124.4, 115.7,
111.8, 60.8, 43.7, 35.5, 33.5;. HRMS (ESI+) (m/z): [M + H+]+
calcd. for C27H24N5O3S2
+, 530.1315; found, 530.1314.
Ethyl 2-(1,3-dioxoisoindolin-2-yl)acetimidate hydrochloride
(39). 2-(1,3-Dioxoisoindolin-2-yl)acetonitrile (3.84 g, 20.6
mmol) was dissolved in a mixture of EtOH (60 ml) and EtOAc
(60 ml). AcCl (14.7 ml, 206 mmol) was then added dropwise
over 30 minutes at 0 °C. Allowed to slowly reach room
temperature and stirring continued for 17 h, then
concentrated to give 5.29 g of a mixture containing 39 (1.93
g, 35%) and ethyl 2-(1,3-dioxoisoindolin-2-yl)acetate as a white
solid. 1H-NMR (400 MHz, CDCl3) δ 7.96–7.92 (m, 2H), 7.83–
7.78 (m, 2H), 4.92 (s, 2H), 4.75 (q, J = 7.1 Hz, 2H), 1.43 (t, J =
7.1 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 173.1, 166.9, 134.8,
131.9, 124.2, 72.6, 38.2, 13.7.
(R)-Methyl 2-((1,3-dioxoisoindolin-2-yl)methyl)-4,5-
dihydrothiazole-4-carboxylate (40). 5.29 g of the mixture
containing 39 (1.93 g, 7.18 mmol) and ethyl 2-(1,3-
dioxoisoindolin-2-yl)acetate was dissolved in DCM (80 ml) and
L-cysteine methyl ester hydrochloride (3.90 g, 22.7 mmol)
followed by Et3N (4.32 ml, 31.0 mmol) were added. The
reaction was stirred at room temperature for 3 days. The
mixture was washed with NaHCO3 (aq) and the aqueous phase
was extracted with EtOAc and DCM. The organic layers were
dried (Na2SO4), filtered and concentrated. Purified using
column chromatography on silica gel (heptane : EtOAc 88 : 12 ≥
0 : 100) to give 40 as a colorless oil (1.39 g, 64%) [α]D 2° (c
0.0035, DCM). 1H-NMR (400 MHz, CDCl3) δ 7.86–7.80 (m, 2H),
7.71–7.66 (m, 2H), 5.10–5.03 (m, 1H), 4.66 (t, J = 1.8 Hz, 2H),
3.72 (s, 3H), 3.58 (dd, J = 11.3, 8.6 Hz, 1H), 3.48 (dd, J = 11.3,
9.6 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ 170.8, 170.0, 167.4,
134.4, 132.1, 123.9, 78.1, 53.0, 39.8, 35.9. HRMS (ESI+) (m/z): [M
+ Na+]+ calcd. for C14H12N2O4SNa
+, 327.0410; found, 327.0411.
(R)-Methyl 8-(1,3-dioxoisoindolin-2-yl)-7-(naphthalen-1-
ylmethyl)-5-oxo-3,5-dihydro-2H-thiazoloĳ3,2-a]pyridine-3-
carboxylate (41). Substituted thiazoline 40 (740 mg, 2.43
mmol) and 5-(1-hydroxy-2-(naphthalen-1-yl)ethylidene)-2,2-
dimethyl-1,3-dioxane-4,6-dione (1.67 g, 5.35 mmol) were
dissolved in DCM (9.35 ml). TFA (205 μl, 2.68 mmol) was
added and the mixture was heated in a sealed vial at 80 °C
for 4 days. More 5-(1-hydroxy-2-(naphthalen-1-yl)ethylidene)-
2,2-dimethyl-1,3-dioxane-4,6-dione (1.67 g, 5.35 mmol) was
added after 24 h, after 48 h, and after 72 h. The reaction was
then quenched with NaHCO3Ĳaq) and extracted with EtOAc.
The organic phase was dried (Na2SO4), filtered and
concentrated. Purified using column chromatography on
silica gel (heptane : EtOAc 88 : 12 ≥ 0 : 100) to give methyl
ester 41 as a brown foam (742 mg, 62%). [α]D −4° (c 0.0025,
DCM); 1H-NMR (400 MHz, CDCl3) δ 7.98–7.91 (m, 2H), 7.76–
7.69 (m, 4H), 7.67 (d, J = 8.3 Hz, 1H), 7.40–7.32 (m, 2H), 7.29
(t, J = 7.4 Hz, 1H), 7.22 (d, J = 6.9 Hz, 1H), 5.79 (s, 1H) 5.54
(dd, J = 8.5, 2.6 Hz, 1H), 4.07, 3.99 (ABq, JAB = 17.1 Hz, 2H),
3.78 (s, 3H), 3.73 (dd, J = 11.9, 8.4 Hz, 1H), 3.53 (dd, J = 11.9,
2.7 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ 167.9, 166.5, 166.4,
160.8, 154.2, 149.4, 134.7, 134.6, 133.8, 132.0, 131.6, 131.4,
131.3, 128.6, 128.1, 128.0, 126.4, 125.7, 125.4, 123.9, 123.9,
123.8, 115.5, 106.7, 63.9, 53.4, 34.7, 32.3. HRMS (ESI+) (m/z):
[M + H+]+ calcd. for C28H21N2O5S
+, 497.1166; found, 497.1166.
8-(1,3-Dioxoisoindolin-2-yl)-7-(naphthalen-1-ylmethyl)-5-
oxo-3,5-dihydro-2H-thiazolo[3,2-a]pyridine-3-carboxylic acid
(42). Methyl ester 41 (1.26 g, 2.54 mmol) was dissolved in
THF (10.3 ml) and LiOH (5.1 ml, 1 M in H2O) was added.
The reaction was stirred for 4 h, then acidified using 1 M
HCl and extracted with EtOAc. The organic phase was dried
(Na2SO4), filtered and concentrated. Redissolved in DMF (15
ml) and AcOH (146 μl) added. Heated to 150 °C for 20 h.
Concentrated and purified using column chromatography on
silica gel (DCM :MeOH 99 : 1 ≥ 88 : 12 with 1% AcOH) to give
carboxylic acid 42 as a brown solid (955 mg, 78%). 1H-NMR
(400 MHz, DMSO-d6) δ 13.60 (br s, 1H), 7.98–7.86 (m, 5H),
7.83–7.73 (m, 2H), 7.48–7.34 (m, 3H), 7.33–7.28 (m, 1H), 5.50
(s, 1H), 5.46 (dd, J = 9.0, 2.4 Hz, 1H), 4.13, 4.07 (ABq, JAB =
17.4 Hz, 2H), 3.95 (dd, J = 11.9, 9.2 Hz, 1H), 3.59 (dd, J =
11.9, 2.1 Hz, 1H). 13C-NMR (100 MHz, DMSO-d6) δ 169.0,
166.4, 166.2, 159.6, 154.0, 150.8, 135.2, 135.2, 133.4, 132.7,
131.2, 130.9, 128.6, 128.0, 127.6, 126.2, 125.7, 125.4, 123.9,
123.8, 123.7, 113.4, 105.3, 63.7, 33.8, 32.0. HRMS (ESI+) (m/z):
[M + H+]+ calcd. for C27H19N2O5S
+, 483.1009; found, 483.1007.
tert-Butyl (8-(1,3-dioxoisoindolin-2-yl)-7-(naphthalen-1-
ylmethyl)-5-oxo-3,5-dihydro-2H-thiazoloĳ3,2-a]pyridin-3-yl)-
carbamate (43). Carboxylic acid 42 (940 mg, 1.95 mmol) was
suspended in dry t-BuOH (20 ml) and DPPA (442 μl, 2.05
mmol) followed by Et3N (285 μl, 2.05 mmol) were added. 3 Å
molecular sieves (enough to cover approximately one third of
the solvent volume) was added to the suspension and the
reaction vessel was sealed. The reaction was heated to 85 °C
for 2 h and then filtered through wool and concentrated.
Purified using column chromatography on silica gel
(heptane : EtOAc 80 : 20 ≥ 0 : 100, the column was prewashed
with heptane : EtOAc : TEA 80 : 20 : 2 to neutralize the silica
gel) to give BOC-protected amine 43 as a pale yellow foam
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(610 mg, 57%). 1H-NMR (600 MHz, CDCl3) δ 7.82–7.76 (m,
2H), 7.71–7.67 (m, 4H), 7.63 (d, J = 8.3 Hz, 1H), 7.34–7.29 (m,
2H), 7.24 (t, J = 7.9 Hz, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.60 (t, J
= 7.4 Hz, 1H), 5.77 (s, 1H), 5.73 (d, J = 7.8 Hz, 1H), 3.97 (s,
2H), 3.66 (dd, J = 11.8, 6.6 Hz, 1H), 3.28 (d, J = 11.8 Hz, 1H),
1.41 (s, 9H). 13C-NMR (151 MHz, CDCl3) δ 166.7, 166.4, 160.0,
153.9, 153.9, 149.0, 134.6, 133.7, 131.9, 131.5, 131.3, 131.2,
128.6, 128.0, 127.9, 126.3, 125.7, 125.3, 123.9, 123.9, 123.7,
115.8, 106.2, 80.8, 69.7, 36.2, 34.6, 28.2. HRMS (ESI+) (m/z):
[M + H+]+ calcd. for C31H28N3O5S
+, 554.1744; found, 554.1742.
2-(3-Amino-7-(naphthalen-1-ylmethyl)-5-oxo-3,5-dihydro-
2H-thiazolo[3,2-a]pyridin-8-yl)isoindoline-1,3-dione (44). BOC-
protected amine 43 (280 mg, 0.51 mmol) was dissolved in
DCM (6 ml) and TFA (2 ml) was added. The reaction was
stirred at room temperature for 2 h. Neutralized with
NaHCO3 (sat. aq) and extracted with EtOAc. The organic
phase was dried (Na2SO4), filtered and concentrated. Purified
using column chromatography on silica gel (EtOAc :MeOH
99 : 1 ≥ 90 : 10) to give amine 44 as a pale yellow foam (201
mg, 88%). 1H-NMR (600 MHz, CDCl3) δ 7.85–7.79 (m, 2H),
7.74–7.68 (m, 4H), 7.68 (d, J = 8.4 Hz, 1H), 7.36–7.30 (m, 2H),
7.29 (t, J = 7.5 Hz, 1H), 7.22 (d, J = 7.0 Hz, 1H), 5.93 (dd, J =
7.3, 1.9 Hz, 1H), 5.81 (s, 1H), 4.01 (s, 2H), 3.67 (dd, J = 11.9,
7.5 Hz, 1H), 3.12 (d, J = 11.9, 1.9 Hz, 1H), 2.59 (s, 2H). 13C-
NMR (151 MHz, CDCl3) δ 166.7, 166.5, 161.3, 154.1, 148.1,
134.6, 133.8, 132.1, 131.6, 131.4, 131.3, 128.6, 128.1, 127.9,
126.4, 125.7, 125.4, 123.9, 123.8, 115.5, 106.2, 74.2, 35.5, 34.6.
HRMS (ESI+) (m/z): [M + H+]+ calcd. for C26H20N3O3S
+,
454.1220; found, 454.1222.
2-(7-(Naphthalen-1-ylmethyl)-5-oxo-3-(4-phenyl-1H-1,2,3-
triazol-1-yl)-3,5-dihydro-2H-thiazoloĳ3,2-a]pyridin-8-yl)-
isoindoline-1,3-dione (45). Amine 44 (500 mg, 1.10 mmol)
was dissolved in dry MeOH (10 ml). K2CO3 (335 mg, 2.43
mmol) and CuSO4 (35.3 mg, 0.22 mmol) followed by
imidazole-1-sulfonyl azide (628 mg, 2.32 mmol) were added.
The mixture was heated to 50 °C for 24 h. Diluted with EtOAc
and washed with brine. The water layer was extracted with
EtOAc. The combined organic layers were dried (Na2SO4),
filtered and concentrated. Rough purification using column
chromatography on silica gel (heptane : EtOAc 90 : 10 ≥ 20 :
80) to give a yellow oil containing the azide. Redissolved in a
mixture of DMF (1.86 ml) and H2O (0.186 ml) and added
sodium ascorbate (61.5 mg, 0.310 mmol), CuSO4 (24.8 mg,
0.155 mmol) and phenyl acetylene (28.4 μl, 0.257 mmol). The
reaction was stirred at room temperature for 3.5 hours.
Diluted with EtOAc and washed with brine. EDTA (50 eq.)
was added and the water phase was then acidified to pH 5
and left to stir overnight. Extracted with EtOAc. The
combined organic layers were dried (Na2SO4), filtered and
concentrated. Purified using column chromatography on
silica gel (heptane : EtOAc 88 : 12 ≥ 0 : 100) to give 1,2,3-
triazole 45 as a colorless solid (9 mg, 1.4%). 1H-NMR (400
MHz, DMSO-d6) δ 8.70 (s, 1H), 8.01–7.89 (m, 4H), 7.89–7.82
(m, 3H), 7.81–7.73 (m, 2H), 7.52–7.38 (m, 5H), 7.36 (t, J = 7.4
Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 5.52 (s, 1H), 4.32 (dd, J =
13.1, 7.6 Hz, 1H), 4.17, 4.10 (ABq, JAB = 17.4 Hz, 2H), 3.87 (d,
J = 12.8 Hz, 1H). 13C-NMR (100 MHz, DMSO-d6) δ 166.3,
166.2, 159.1, 155.3, 151.4, 145.9, 135.3, 135.2, 133.4, 132.4,
131.1, 130.9, 130.1, 129.0, 128.6, 128.2, 128.1, 127.6, 126.3,
125.8, 125.5, 125.3, 124.0, 123.9, 123.6, 121.8, 113.6, 105.8,
74.1, 35.0, 33.9. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C34H24N5O3S
+, 582.1594; found, 582.1593.
N-(7-(Naphthalen-1-ylmethyl)-5-oxo-3-(4-phenyl-1H-1,2,3-
triazol-1-yl)-3,5-dihydro-2H-thiazoloĳ3,2-a]pyridin-8-yl)-
methanesulfonamide (46). 1,2,3-Triazole 45 (8 mg, 0.014
mmol) was suspended in EtOH (10 ml) and methyl amine
(2.5 ml, 40% in H2O) was added. The reaction was stirred at
room temperature for 20 hours. Most of the EtOH was
removed under vacuum and the remaining solution was
extracted with EtOAc. The organic phase was dried (Na2SO4),
filtered and concentrated. The residue was redissolved in
pyridine (0.28 ml) and MsCl (3.2 μl, 0.04 mmol) was added.
Stirred at room temperature for 26 h. Additional MsCl was
added after 19 h (3.2 μl, 0.04 mmol) and after 22 h (6.4 μl,
0.08 mmol). The reaction was concentrated and redissolved
in MeOH (250 μl) and THF (600 μl). LiOH (700 μl, 1 M in
H2O) was added and the reaction was stirred at room
temperature for 2 h. The mixture was diluted with EtOAc and
washed with brine. The organic phase was dried (Na2SO4),
filtered and concentrated. Purified using HPLC (H2O :MeCN
95 : 5 ≥ 0 : 100 with 0.75% formic acid over 40 minutes) and
then freeze dried to give amine 46 as a colorless solid (7 mg,
99%). 1H-NMR (600 MHz, CDCl3) δ 8.20 (s, 1H), 7.87–7.75 (m,
5H), 7.48–7.35 (m, 5H), 7.34–7.30 (m, 2H), 7.24 (d, J = 7.1 Hz,
1H), 6.10 (s, 1H), 5.66 (s, 1H), 4.50, 4.33 (ABq, JAB = 17.7 Hz,
2H), 4.27 (d, J = 12.5 Hz, 1H), 4.06 (dd, J = 12.6, 7.3 Hz, 1H),
3.23 (s, 3H); 13C-NMR (151 MHz, CDCl3) δ 160.3, 157.9, 149.8,
148.1, 134.1, 132.6, 132.0, 129.9, 129.0, 128.9, 128.7, 128.4,
128.1, 126.7, 126.1, 126.0, 125.7, 124.2, 121.3, 116.1, 111.3,
73.8, 44.0, 35.7, 33.6. HRMS (ESI+) (m/z): [M + H+]+ calcd. for
C27H24N5O3S2
+, 530.1315; found, 530.1313.
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AUC Area under curve
C. trachomatis Chlamydia trachomatis
CL Clearance
DIPEA N,N-Diisopropylethylamine
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EB Elementary body
FBS Fetal bovine serum
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxide
hexafluorophosphate
HBSS Hanks balanced salt solution
IFU Inclusion forming unit
MOI Multiplicity of infection
MWI Microwave irradiation
RB Reticulate body
rt Room temperature
TBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate
IV Intravenously
PO Per oss (oral)
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